

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 9/12, C07K 16/40, A61K 38/45</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/32609</b> <b>(43) International Publication Date:</b> 1 July 1999 (01.07.99)
<b>(21) International Application Number:</b> PCT/SE98/02384 <b>(22) International Filing Date:</b> 18 December 1998 (18.12.98)  <b>(30) Priority Data:</b> 9704788-0                      19 December 1997 (19.12.97)      SE 9802292-4                      26 June 1998 (26.06.98)                      SE  <b>(71) Applicant (for all designated States except US):</b> KAROLIN- SKA INNOVATIONS AB [SE/SE]; S-171 77 Stockholm (SE).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> TOFTGÅRD, Rune [SE/SE]; Sättagårdsvägen 209, S-127 36 Skärholmen (SE). ZAPHIROPOULOS, Peter, G. [GR/SE]; Tullinge Strand 96, S-146 54 Tullinge (SE).  <b>(74) Agents:</b> BERG, S., A. et al.; Albihns Patentbyrå Stockholm AB, P.O. Box 5581, S-114 85 Stockholm (SE).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>

**(54) Title:** MOLECULES ASSOCIATED WITH THE HUMAN FUSED GENE**(57) Abstract**

The present invention relates to proteins, polypeptides and nucleotides related to the human homologue of the *Drosophila* fused gene, which is involved in the transduction of signals in the *hedgehog-patched* (HH-PTC) pathway. The invention also relates to antibodies raised against the polypeptides according to the invention. The molecules according to the invention are useful in diagnostic and therapeutic methods relating to conditions associated with defects in said pathway, especially cancer and certain malformations. Other fields of application of the molecules according to the invention are e.g. studies of embryonic development, gene transcription and tissue repair.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## MOLECULES ASSOCIATED WITH THE HUMAN FUSED GENE

### Technical field

The present invention relates to novel molecules, such as proteins, polypeptides and nucleotides, involved in the transduction of signals in the *hedgehog-patched* (HH-PTC) pathway, which takes place during the development of the cells of a human  
5 body. The invention also relates to certain advantageous uses of the molecules according to the invention in diagnosis and therapy.

### Background

In the study of the development of cells, fruit flies have extensively been used as a  
10 model, as they are less complex than mammalian cells.

Pattern formation takes place through a series of logical steps, reiterated many times during the development of an organism. Viewed from a broader evolutionary perspective, across species, the same sort of reiterative pattern formations are seen. The  
15 central dogma of pattern formation has been described (Lawrence and Struhl, 1996). Three interlocking and overlapping steps are defined. Firstly, positional information in the form of morphogen gradients allocate cells into non-overlapping sets, each set founding a compartment. Secondly, each of these compartments acquire a genetic address, as a result of the function of active "selector" genes, that specify cell fate  
20 within a compartment and also instruct cells and their descendents how to communicate with cells in neighboring compartments. The third step involves interactions between cells in adjacent compartments, initiating new morphogen gradients, which directly organize the pattern.

25 Taking these steps in greater detail, one finds the first step in patterning to be the definition of sets of cells in each primordium. Cells are allocated according to their positions with respect to both dorsoventral and anterior/posterior axes by morphogen gradients. Allocation of cells in the dorsoventral axis constitutes the germ layers, such as mesoderm or neurectoderm.

In segmentation, the second step (the specification of cell fate in each compartment) is carried out by the gene *engrailed* and elements of the bithorax complex. *Engrailed* defines anterior and posterior compartments both in segmentation and in limb specification.

5

The third step in pattern formation, secretion of morphogens, functions to differentiate patterns within compartments (and thereby establish segment polarity). Initially, all cells within a compartment are equipotent, but they become diversified to form pattern. Pattern formation depends on gradients of morphogens, gradients initiated along compartment boundaries. Such gradients are established by a short-range signal induced in all the cells of the compartment in which the above mentioned selector gene *engrailed* is active. For segment polarity, this signal is Hedgehog. In the adjacent compartment the selector gene is inactive, ensuring that the cells are sensitive to the signal. The Hedgehog signal range is probably only a few rows of cells wide; responding cells become a linear source of a long-range morphogen, that diffuses outward in all directions. There are three known Hedgehogs, Sonic (SHH), Indian (IHH) and Desert (DHH). The proteins they encode can substitute each for each other, but in wildtype animals, their distinct distributions result in unique activities. SHH controls the polarity of limb growth, directs the development of neurons in the ventral neural tube and patterns somities. IHH controls endochondral bone development and DHH is necessary for spermiogenesis. Vertebrate hedgehog genes are expressed in many other tissues, including the peripheral nervous system, brain, lung, liver, kidney, tooth primordia, genitalia and hindgut and foregut endoderm.

Thus, segment polarity genes have been identified in flies as mutations, which change the pattern of structures of the body segments. Mutations in these genes cause animals to develop the changed patterns on the surfaces of body segments, the changes affecting the pattern along the head to tail axis. For example, mutations in the gene *patched* cause each body segment to develop without the normal structures in the center of each segment. Instead there is a mirror image of the pattern normally

found in the anterior segment. Thus, cells in the center of the segment make the wrong structures, and point them in the wrong direction with reference to the over all head-to-tail polarity of the animal.

5 About sixteen genes in the class are known. The encoded proteins include kinases, transcription factors, a cell junction protein, two secreted proteins called wingless (WG) and the above mentioned Hedgehog (HH), a single transmembrane protein called patched (PTC) and some novel proteins not related to any known protein. All of these proteins are beleived to work together in signaling pathways that inform  
10 cells about their neighbors in order to set cell fates and polarities.

PTC has been proposed as a receptor for HH protein based on genetic experiments in flies. A model for the relationship is that PTC acts through a largely unknown pathway to inactivate both its own transcription and the transcription of the *wingless*  
15 segment polarity gene. This model proposes that HH protein, secreted from adjacent cells, binds to the PTC receptor, inactivates it and thereby prevents PTC from turning off its own transcription or that of *wingless*. A number of experiments have shown coordinate events between PTC and HH.

20 WO 96/11260 discloses the isolation of *patched* genes and the use of the PTC protein to identify ligands, other than the established ligand Hedgehog, that bind thereto. However, even though it is briefly suggested that drugs may be identified which can prevent the transduction of signals by the PTC protein, there are no teachings as regards how such signals are transduced.

25

In order to elucidate how the Hedgehog elecits signal transduction, a large complex containing the kinesin-related protein *costa12* has been proposed (Robbins et al; Cell: July 25, 1997, 90(2), p. 225-34). Said complex includes the products of at least three genes: *fused* (a protein-serine/threonine kinase), *cubitus interruptus* (a tran-  
30 scription factor) and *costa12* (a kinesin-like protein). It is concluded that in Droso-

phila, the complex may facilitate signaling from HH by governing access of the cubitus interruptus protein to the nucleus.

Therond et al have also studied signaling from Hedgehog in *Drosophila* (Proc. Natl. Acad. Sci. USA, April 30, 1996, 93(9), p. 4224-8). The *Drosophila* gene *fused* (*fu*) encodes a serine/threonine-protein kinase, that genetic experiments have implicated in signaling initiated by hedgehog. It is proposed that the fused protein is phosphorylated during the course of *Drosophila* embryogenesis, as a result of hedgehog activity. The conclusion of this reference is, that a reconstruction of signaling from hedgehog in cell culture should provide further access to the mechanisms by which the hedgehogs acts.

Thus, even though the gene *fused* (*fu*) has been identified in *Drosophila*, it has not been isolated from human beings in the prior art. The prior art teachings about the interactions between *hedgehog* and *patched* in mammals are not at all sufficient for practical application in regard of human beings. Firstly, there is a need of a better understanding of how signals are actually elicited and transduced between the *hedgehog* ligand and the *patched* receptor. Secondly, the human homologues of the genes and proteins implicated in this pathway must also be fully sequenced, and the cDNA thereof identified, in order to enable recombinant reproduction thereof.

However, due to substantial genetic differences between fruit flies and human beings and the complex nature of the human genome, the isolation of the human homologues to genes identified in fruit flie is in no way a straightforward task.

#### Summary of the invention

The present invention fulfill the above defined desire by providing novel human homologues to molecules associated with the *Drosophila* *fused* gene and implicated in the transduction of the signals that are elicited by the interaction between the *patched* receptor (sometimes denoted the NBCCS gene) and any one of the hedgehog

ligands. Thus, the present gene has according to the invention been localised to human chromosome 15q22-24. The molecules according to the invention are nucleic acids as well as polypeptides and proteins encoded thereof, which are useful within several fields, including the study of different conditions, such as cancer and development of cancer therapies, the regulation of gene transcription, studies of embryonic development, tissue repair etc. Two specific syndromes have been mapped to the 15q22-24 genomic region, namely "Bardet-Biedl Syndrome" and "Cerebral Gigantism/Sotus Syndrome" (15q22 or 5q35). The latter is a cancer predisposition syndrome also involving craniofacial defects and growth disturbances making the FUH an interesting candidate gene. The great importance of the present pathway also makes the FUH a potential "oncogene" or "tumor suppressor gene".

The present invention provides an important basic understanding of a signaling pathway that is central to normal development and often disrupted in disease. The new knowledge will also be of great value when considering new therapeutic strategies involving modification of SHH-PTCH signaling. Potential areas include tissue repair/wound healing (brain, bone, cartilage, skin), neurodegenerative disease, testicular function and cancer.

#### 20 Detailed description of the invention

Accordingly, in a first aspect, the present invention relates to a protein molecule capable of being involved in eliciting intracellular signaling in the human HH-PTC pathway, preferably the SHH-PTC pathway. The protein according to the invention exhibits a substantial similarity with the sequence disclosed in SEQ ID NO 2 of the Sequence Listing shown below. In a particular embodiment, the protein according to the invention is comprised of about 80% of said sequence and in a specific embodiment, it is comprised of substantially all of said amino acid sequence. However, it should probably include at least about 60% of said sequence in order to exhibit the advantageous properties as disclosed in the present application. As someone of skill in this area easily realises, the percentages given herein will depend on possible

further added fragments or sequence parts, as a protein exhibiting 80% of the sequence of SEQ ID NO 2, to which a further fragment has been added, naturally in itself will include a smaller percentage of the present sequence. Thus, it is to be understood that any sequence including the herein given percentages of SEQ ID NO 2 as disclosed is within the scope of the invention. Analogues of, and functional equivalents to, the proteins according to the invention are also encompassed by the present invention. Thus, the protein according to the invention is an isolated human *fused* protein, (FUH).

10 According to the present invention, it has been found that the human homologue of *Drosophila fused* is an intracellular transducer of the signal elicited at the cell membrane by interaction of ligands, such as sonic hedgehog (SHH), indian hedgehog (IHH) and desert hedgehog (DHH), with the receptor human homologue of *Drosophila patched* (PTC). This interaction leads to initiation of a signaling pathway by  
15 allowing PTC or its coreceptor, human homologue of *Drosophila smoothened* (SMOH), to activate intracellular signal transducers. As mentioned above, in *Drosophila* cells, *fused* interacts with the microtubule associated protein costal-2 (cos-2) and the transcription factor cubitus interruptus (ci). The latter has human homologues denoted GLI 1-3.

20

Thus, in a second aspect, the present invention also relates to polypeptides comprised of suitable fragments or parts of the amino acid sequence of the above described protein. Thus, such a polypeptide is also associated with the HH-PTC pathway, such as SHH-PTC, and is comprised of a subsequence of up to about 20, such as 8-15,  
25 preferably 9-12 and most preferred 10 contiguous amino acids of the sequence disclosed in SEQ ID NO 2 or conservative substitutions of said sequence. The polypeptide according to the invention may be encoded by a nucleic acid amplified from genomic DNA or RNA using appropriate primers which the skilled man in this field easily chooses. In a specific embodiment, the polypeptide according to the invention  
30 is presented as an antigen, which elicits the production of an antibody which speci-

fically binds to a polypeptide encoded by a nucleic acid according to SEQ ID NO 1, and said polypeptide does not bind to antisera raised against a polypeptide encoded by a nucleic acid sequence according to SEQ ID NO 1, which has been fully immunosorbed with a polypeptide encoded by a sequence of SEQ ID NO 2.

5

A third aspect of the present invention is a nucleic acid encoding any one of the above defined proteins or polypeptides. In a preferred embodiment, the nucleic acid according to the invention is such a DNA sequence as disclosed in SEQ ID NO 1.

Thus, according to the present invention, for the first time, a human homologue of the *Drosophila fused* gene has been isolated, the cDNA thereof has been established, sequenced and cloned. The complete cDNA sequence thereof is disclosed in SEQ ID NO 1. The present invention also encompasses nucleotides that hybridises to part or all of the sequence of SEQ ID NO 1 as well as to nucleotides hybridising to the DNA encoding the proteins and polypeptides according to the invention. Such nucleotides may e.g. be RNA sequences.

15

The human homologue according to the invention exhibits an amino acid similarity with *Drosophila fused* of 54%. Within the kinase domain, the similarity increases to 59,5%. Further, the present human homologue of *fused* exhibits an amino acid identity with *Drosophila fused* of 33,5%. Within the kinase domain, the identity increases to 37%.

20

In a fourth aspect, the present invention also relates to a vector comprising a nucleic acid according to the invention, such as part of, or all of, the DNA sequence disclosed in SEQ ID NO 1. The vector preferably include the above described nucleic acid operably linked, i.e. under the control of, a promoter; either constitutive or inducible. The vector can also include suitable initiation and termination codons.

25

In addition, the invention also relates to an expression cassette comprising any one of the nucleic acids according to the invention. Accordingly, yet another aspect of the invention is a cell comprising an expression cassette according to the invention. In one further aspect, the invention relates to an antibody which specifically binds to  
5 such a polypeptide as defined above, which preferably comprises at least about 10, more preferably at least 20, 40 or 50 and most preferably at least 100 or 200, or even 400, amino acids. Alternatively, the antibody binds to a protein encoded by essentially all of the sequence as disclosed in SEQ ID NO 1. The antibody is polyclonal or monoclonal, preferably, it is a monoclonal antibody. It can be humanized or human.

10

One specific embodiment of the present invention is a kinase-activating substance, which is capable of activating a protein according to the invention. Alternatively, the invention relates to a kinase-inhibiting substance. Such kinase-regulating substances may be used as drugs. Pharmaceutical compositions to this end comprise a  
15 kinase-activator or kinase-inhibitor capable of influencing the protein according to the invention together with a pharmaceutically acceptable carrier.

The present invention also relates to a cell, such as a recombinant cell, e.g. hybridomas or triomas, expressing such an antibody as defined above. Also encompassed  
20 by the invention is the use of such an antibody as a medicament or in the manufacture of a specific drug or therapy.

Thus, another aspect of the invention is a pharmaceutical composition which comprises a molecule selected from the group consisting of a vector encoding a polypeptide according to the invention or a subsequence thereof, a polypeptide according to  
25 the invention or a subsequence thereof and an antibody raised against the present polypeptides together with a pharmaceutically acceptable carrier.

Yet another aspect of the invention is a kit for detection of a human *fused* gene,  
30 which kit comprises a nucleic acid sequence capable of hybridising to an essential

part of the sequence disclosed in SEQ ID NO 1, preferably under stringent conditions. The invention also relates to a kit for detection of a protein encoded by a human *fused* gene sequenced according to the present invention, comprising a container containing an antibody as defined above.

5

In a last aspect, the invention also relates to methods for detecting any deviations from a normal human *fused* gene. The method includes the steps of a) providing a biological sample of the organism and b) detecting a human *fused* gene or gene product in the sample. The provision of a biological sample and detection methods will be described below.

10

The invention also relates to diagnostic and prognostic methods, wherein mutations in pathway components are detected, as well as to kits for performing such methods.

15 Finally, the present invention also relates to methods of treatment, wherein the above defined molecules are used. Conditions that may be contemplated include cancers, such as basal cell cancer of the skin, medulloblastomas, trichoepitheliomas and breast cancer, conditions caused by defects in brain development, lung development, tooth and hair development and sperm formation, and tissues repair. The present  
20 molecules are also useful in gene therapy. The methods according to the invention can involve transfecting cells of a mammal with a vector expressing a polypeptide or antibody according to the invention. The transfection can be *in vivo* or *ex vivo*. *Ex vivo* transfection is suitably followed by re-infusing the cells into the organism. Other methods involve administering to the mammal, e.g. a human, of a therapeutically effective dose of a composition comprising a polypeptide according to the  
25 invention and a pharmacological excipient and/or carrier.

### Definitions

30 The term "antibody" refers to a polypeptide substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments thereof which specifically bind

and recognize an analyte (antigen). The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD, and IgE, respectively.

An exemplary immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kD) and one "heavy" chain (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain ( $V_L$ ) and variable heavy chain ( $V_H$ ) refer to these light and heavy chains, respectively.

Antibodies exist e.g., as intact immunoglobulins or as a number of well characterized fragments produced by digestion with various peptidases. Thus, for example, pepsin digests an antibody below the disulfide linkages in the hinge region to produce  $F(ab)'_2$ , a dimer of Fab which itself is a light chain joined to  $V_H-C_H1$  by a disulfide bond. The  $F(ab)'_2$  may be reduced under mild conditions to break the disulfide linkage in the hinge region, thereby converting the  $F(ab)'_2$  dimer into an Fab' monomer. The Fab' monomer is essentially a Fab with part of the hinge region (see, *Fundamental Immunology*, Third Edition, W.E. Paul, ed., Raven Press, N.Y. 1993). While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such fragments may be synthesized *de novo* either chemically or by utilizing recombinant DNA methodology. Thus, the term antibody, as used herein, also includes antibody fragments either produced by the modification of whole antibodies or those synthesized *de novo* using recombinant DNA methodologies (e.g., single chain Fv).

A "chimeric antibody" is an antibody molecule in which (a) the constant region, or a portion thereof, is altered, replaced or exchanged so that the antigen binding site

(variable region) is linked to a constant region of a different or altered class, effector function and/or species, or an entirely different molecule which confers new properties to the chimeric antibody, *e.g.*, an enzyme, toxin, hormone, growth factor, drug, *etc.*; or (b) the variable region, or a portion thereof, is altered, replaced or exchanged with a variable region having a different or altered antigen specificity.

The term "immunoassay" is an assay that utilizes an antibody to specifically bind an analyte. The immunoassay is characterized by the use of specific binding properties of a particular antibody to isolate, target, and/or quantify the analyte.

10

The terms "isolated" "purified" or "biologically pure" refer to material which is substantially or essentially free from components which normally accompany it as found in its native state.

15 The term "nucleic acid" refers to a deoxyribonucleotide or ribonucleotide polymer in either single- or double-stranded form, and unless otherwise limited, encompasses known analogs of natural nucleotides that can function in a similar manner as naturally occurring nucleotides.

20 The terms "polypeptide", "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical analogue of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers.

25

A "label" is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include  $^{32}\text{P}$ , fluorescent dyes, electron-dense reagents, enzymes (*e.g.*, as commonly used in a ELISA), biotin, dioxigenin, or haptens and proteins for which antisera or monoclonal antibodies are available (*e.g.*, the peptide of SEQ ID NO 1 can be made detectable, *e.g.*, by

30

incorporating a radio-label into the peptide, and used to detect antibodies specifically reactive with the peptide).

As used herein a "nucleic acid probe" is defined as a nucleic acid capable of binding to a target nucleic acid of complementary sequence through one or more types of chemical bonds, usually through complementary base pairing, usually through hydrogen bond formation. As used herein, a probe may include natural (*i.e.* A, G, C, U or T) or modified bases (7-deazaguanosine, inosine, *etc.*) In addition, the bases in a probe may be joined by a linkage other than a phosphodiester bond, so long as it does not interfere with hybridization. Thus, for example, probes may be peptide nucleic acids in which the constituent bases are joined by peptide bonds rather than phosphodiester linkages. It will be understood by one of skill in the art that probes may bind target sequences lacking complete complementarity with the probe sequence depending upon the stringency of the hybridization conditions. The probes are preferably directly labeled as with isotopes, chromophores, lumiphore, chromogens, or indirectly labeled such as with biotin to which a streptavidin complex may later bind. By assaying for the presence or absence of the probe, one can detect the presence or absence of the select sequence or subsequence.

A "labeled nucleic acid probe" is a nucleic acid probe that is bound, either covalently, through a linker, or through ionic, van der Waals or hydrogen bonds to a label such that the presence of the probe may be detected by detecting the presence of the label bound to the probe.

The term "target nucleic acid" refers to a nucleic acid (often derived from a biological sample), to which a nucleic acid probe is designed to specifically hybridize. It is either the presence or absence of the target nucleic acid that is to be detected, or the amount of the target nucleic acid that is to be quantified. The target nucleic acid has a sequence that is complementary to the nucleic acid sequence of the corresponding probe directed to the target. The term target nucleic acid may refer to the specific

subsequence of a larger nucleic acid to which the probe is directed or to the overall sequence (*e.g.*, gene or mRNA) whose expression level it is desired to detect. The difference in usage will be apparent from the context.

5 "Subsequence" refers to a sequence of nucleic acids or amino acids that comprise a part of a longer sequence of nucleic acids or amino acids (*e.g.*, polypeptide), respectively.

The term "recombinant" when used with reference to a cell, or nucleic acid, or vector, indicates that the cell, or nucleic acid, or vector, has been modified by the introduction of a heterologous nucleic acid or the alteration of a native nucleic acid, or that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all.

15 The term "identical" in the context of two nucleic acids or polypeptide sequences refers to the residues in the two sequences which are the same when aligned for maximum correspondence. Optimal alignment of sequences for comparison can be conducted, *e.g.*, by the local homology algorithm of Smith and Waterman (1981) *Adv. Appl. Math.* 2: 482, by the homology alignment algorithm of Needleman and Wunsch (1970) *J. Mol. Biol.* 48:443, by the search for similarity method of Pearson and Lipman (1988) *Proc. Natl. Acad. Sci. USA* 85: 2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI) or by inspection.

An additional algorithm that is suitable for determining sequence similarity is the BLAST algorithm, which is described in Altschul *et al.* (1990) *J. Mol. Biol.* 215: 403-410. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>).

This algorithm involves first identifying high scoring sequence pair (HSPs) by identifying short words of length W in the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul *et al*, *supra*.) These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a word length (W) of 11, the BLOSUM62 scoring matrix (*see* Henikoff and Henikoff (1992) *Proc. Natl. Acad. Sci. USA* 89: 10915-10919) alignments (B) of 50, expectation (E) of 10, M=5, N=4, and a comparison of both strands.

The BLAST algorithm performs a statistical analysis of the similarity between two sequences; *see e.g.*, Karlin and Altschul (1993) *Proc. Nat'l Acad. Sci. USA* 90: 5873-5787. One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a *fused* gene or cDNA if the smallest sum probability in a comparison of the test nucleic acid to a *fused* nucleic acid is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

The term "substantial identity" or "substantial similarity" in the context of a polypeptide indicates that a polypeptides comprises a sequence with at least 70% sequence identity to a reference sequence, or preferably 80%, or more preferably

85% sequence identity to the reference sequence, or most preferably 90% identity over a comparison window of about 10-20 amino acid residues. An indication that two polypeptide sequences are substantially identical is that one peptide is immunologically reactive with antibodies raised against the second peptide. Thus, a polypeptide is substantially identical to a second polypeptide, for example, where the two peptides differ only by a conservative substitution.

An indication that two nucleic acid sequences are substantially identical is that the polypeptide which the first nucleic acid encodes is immunologically cross reactive with the polypeptide encoded by the second nucleic acid.

Another indication that two nucleic acid sequences are substantially identical is that the two molecules hybridize to each other under stringent conditions.

"Bind(s) substantially" refers to complementary hybridization between a probe nucleic acid and a target nucleic acid and embraces minor mismatches that can be accommodated by reducing the stringency of the hybridization media to achieve the desired detection of the target polynucleotide sequence.

The phrase "hybridizing specifically to", refers to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence under stringent conditions when that sequence is present in a complex mixture (*e.g.*, total cellular) DNA or RNA. The term "stringent conditions" refers to conditions under which a probe will hybridize to its target subsequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point  $T_m$  for the specific sequence at a defined ionic strength and pH. The  $T_m$  is the temperature (under defined ionic strength, pH, and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at

equilibrium. (As the target sequences are generally present in excess, at  $T_m$ , 50% of the probes are occupied at equilibrium). Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M Na ion, typically about 0.01 to 1.0 M Na ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (*e.g.*, 10 to 50 nucleotides) and at least about 60°C for long probes (*e.g.*, greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide.

The phrases "specifically binds to a protein" or "specifically immunoreactive with", when referring to an antibody refers to a binding reaction which is determinative of the presence of the protein in the presence of a heterogeneous population of proteins and other biologics. Thus, under designated immunoassay conditions, the specified antibodies bind preferentially to a particular protein and do not bind in a significant amount to other proteins present in the sample. Specific binding to a protein under such conditions requires an antibody that is selected for its specificity for a particular protein. A variety of immunoassay formats may be used to select antibodies specifically immunoreactive with a particular protein. For example, solid-phase ELISA immunoassays are routinely used to select monoclonal antibodies specifically immunoreactive with a protein. See Harlow and Lane (1988) *Antibodies, A Laboratory Manual*, Cold Spring Harbour Publications, New York, for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity.

A "conservative substitution", when describing a protein, refers to a change in the amino acid composition of the protein that does not substantially alter the protein's activity. Thus, "conservatively modified variations" of a particular amino acid sequence refers to amino acid substitutions of those amino acids that are not critical for protein activity or substitution of amino acids with other amino acids having similar properties (*e.g.*, acidic, basic, positively or negatively charged, polar or non-polar, *etc.*) such that the substitutions of even critical amino acids do not substantially alter activity. Conservative substitution tables providing functionally similar

amino acids are well known in the art. The following six groups each contain amino acids that are conservative substitutions for one another:

- 1) Alanine (A), Serine (S), Threonine (T);
- 2) Aspartic acid (D), Glutamic acid (E);
- 5 3) Asparagine (N), glutamine (Q);
- 4) Arginine (R), Lysine (K);
- 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and
- 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

See also, Creighton (1984) *Protein*, W.H. Freeman and Company. In addition, individual substitutions, deletions or additions which alter, add or delete a single amino acid or a small percentage of amino acids in an encoded sequence are also "conservatively modified variations".

A "gene product", as used herein, refers to a nucleic acid whose presence, absence, quantity, or nucleic acid sequence is indicative of a presence, absence, quantity, or nucleic acid composition of the gene. Gene products thus include, but are not limited to, an mRNA transcript a cDNA reverse transcribed from an mRNA, an RNA transcribed from that cDNA, a DNA amplified from the cDNA, an RNA transcribed from the amplified DNA or subsequences of any of these nucleic acids. Polypeptides expressed by the gene or subsequences thereof are also gene products. The particular type of gene product will be evident from the context of the usage of the term.

## EXPERIMENTAL

### General methods

#### 25 I. Uses of the *fused* cDNA

Among other applications, detection of defective *fused* gene expression is of clinical value. The presence of a *fused* gene, cDNA, mRNA, protein or subsequences of the gene, cDNA or protein in a biological sample is useful; e.g. as a marker to assess *in vivo* and/or *in situ* RNA transcription and/or translation, in cancer diagnostics, in prophylaxis etc. Full-length *fused* cDNA, individual exons, or subsequences thereof

are also useful as probes (particularly when labeled) for the detection of the presence or absence and/or quantification of normal or abnormal (e.g. truncated or mutated) *fused* DNA or RNA in a biological sample. The labeled probes can also be useful as in karyotyping analysis as markers of the *fused* gene.

- 5 The proteins and polypeptides according to the invention are also useful as lead compounds in the design of organic molecules resembling the native protein, fully or in part. The designed molecules preferably exhibits the activity of the native one. Methods for protein mimicking are today used widely and the skilled man can perform such a method using the present molecules as lead compounds with reference
- 10 to the literature and well known techniques. In addition, the molecules according to the invention are also useful in screening for various substances.

Further, vectors according to the invention may be used for expression of those proteins to provide immunogens for antibody production. Vectors encoding the present proteins and /or polypeptides are also useful for transforming cells *in vitro* or *in vivo* to express the proteins and/or polypeptides.

15

Cells and/or tissues expressing the *fused* gene may be used to monitor expression levels of *fused* polypeptides in a wide variety of contexts.

20

## II. The *fused* gene

### A) The human *fused* gene (FUH)

SEQ ID NO 1 provides the cDNA sequence for the largest nucleic acid according to the invention, while SEQ ID NO 2 provides the corresponding protein sequence.

25

### B) Isolation of cDNA and/or probes.

The nucleic acids of the present invention are cloned, or amplified by *in vitro* methods, such as the polymerase chain reaction (PCR), the ligase chain reaction (LCR), the transcription-based amplification system (TAS), the self-sustained sequence

30

replication system (SSR). A wide variety of cloning and *in vitro* amplification methodologies are well-known to persons of skill. Examples of these techniques and instructions sufficient to direct persons of skill through many cloning exercises are found in Berger and Kimmel, *Guide to Molecular Cloning Techniques, Methods in Enzymology* 152 Academic Press, Inc., San Diego, CA (Berger); Sambrook *et al.* (1989) *Molecular Cloning - A Laboratory Manual* (2nd ed.) Vol. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor Press, NY, (Sambrook *et al.*); *Current Protocols in Molecular Biology*, F.M. Ausubel *et al.*, Current Protocols, a joint venture between Greene Publishing Associates, Inc. And John Wiley & Sons, Inc., (1994 Supplement) (Ausubel); Cashion *et al.*, U.S. patent number 5,017,478; and Carr, European Patent No. 0,246,864. Examples of techniques sufficient to direct persons of skill through *in vitro* amplification methods are found in Berger, Sambrook, and Ausubel, as well as Mullis *et al.*, (1987) U.S. Patent No. 4,683,202; *PCR Protocols A Guide to Methods and Applications* (Innis *et al.* Eds) Academic Press Inc. San Diego, CA (1990) (Innis); Arnheim & Levinson (October 1, 1990) *C&EN* 36-47; *The Journal Of NIH Research* (1991) 3: 81-94 (Kwoh *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86: 1173; Guatelli *et al.* (1990) *Proc. Natl. Acad. Sci. USA* 87, 1874; Lomell *et al.* (1989) *J. Clin. Chem.*, 35: 1826; Landegren *et al.*, (1988) *Science*, 241: 1077-1080; Van Brunt (1990) *Biotechnology*, 8: 291-294; Wu and Wallace, (1989) *Gene*, 4: 560; and Barringer *et al.* (1990) *Gene*, 89: 117.

In one preferred embodiment, the human *fused* cDNA can be isolated by routine cloning methods. The cDNA sequence provided in SEQ ID NO: 1 can be used to provide probes that specifically hybridize to the *fused* gene, in a genomic DNA sample, or to the *fused* mRNA, in a total RNA sample (*e.g.*, in a Northern blot). Once the target *fused* nucleic acid is identified (*e.g.*, in a Southern blot), it can be isolated according to standard methods known to those of skill in the art (*see, e.g.*, Sambrook *et al.* (1989) *Molecular Cloning: A Laboratory Manual*, 2nd Ed. Vols. 1-3, Cold Spring Harbor Laboratory; Berger and Kimmel (1987) *Methods in Enzymology*, Vol. 152: *Guide to Molecular Cloning Techniques*, San Diego: Academic

press, Inc.; or Ausubel *et al.* (1987) *Current Protocols in Molecular Biology*, Greene Publishing and Wiley-Interscience, New York).

In another preferred embodiment, the human *fused* cDNA is isolated by amplification methods, such as polymerase chain reaction (PCR).

### C) Labeling of nucleic acid probes.

Where the *fused* cDNA or its subsequences are to be used as nucleic acid probes, it is often desirable to label the sequences with detectable labels. The labels may be incorporated by any of a number of means well known to those of skill in the art. However, in a preferred embodiment, the label is simultaneously incorporated during the amplification step in the preparation of the sample nucleic acids. Thus, for example, polymerase chain reaction (PCR) with labeled primers or labeled nucleotides will provide a labeled amplification product. In another preferred embodiment, transcription amplification using a labeled nucleotide (*e.g.* fluorescein-labeled UTP and/or CTP) incorporates a label into the transcribed nucleic acids.

Alternatively, a label may be added directly to an original nucleic acid sample (*e.g.*, mRNA, polyA mRNA, cDNA, *etc.*) or to the amplification product after the amplification is completed. Means of attaching labels to nucleic acids are well known to those of skill in the art and include, for example nick translation or end labeling (*e.g.* with a labeled RNA) by kinasing of the nucleic acid and subsequent attachment (ligation) of a nucleic acid linker joining the sample nucleic acid to a label (*e.g.*, a fluorophore).

25

Detectable labels suitable for use in the present invention include any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means. Useful labels in the present invention include biotin for staining with labeled streptavidin conjugate, magnetic beads (*e.g.*, Dynabeads™), fluorescent dyes (*e.g.*, fluorescein, texas red, thodamine, green fluorescent

30

protein, and the like), radiolabels (e.g.,  $^3\text{H}$ ,  $^{125}\text{I}$ ,  $^{35}\text{S}$ ,  $^{14}\text{C}$ , or  $^{32}\text{P}$ ), enzymes (e.g., horse radish peroxidase, alkaline phosphatase and others commonly used in an ELISA), and colorimetric labels such as colloidal gold or colored glass or plastic (e.g., polystyrene, polypropylene, latex, etc.) beads. Patents teaching the use of such labels  
5 include U.S. Patent Nos. 3,871,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241.

Means of detecting such labels are well known to those of skill in the art. Thus, for example, radiolabels may be detected using photographic film or scintillation counters, fluorescent markers may be detected using a photodetector to detect emitted  
10 light. Enzymatic labels are typically detected by providing the enzyme with a substrate and detecting the reaction product produced by the action of the enzyme on the substrate, and colorimetric labels are detected by simply visualizing the colored label.

### 15 III. Antibodies to the *fused* polypeptide(s).

Antibodies are raised to the *fused* polypeptides of the present invention, including individual, allelic, strain, or species variants, and fragments thereof, both in their naturally occurring (full-length) forms and in recombinant forms. Additionally, antibodies are raised to these polypeptides in either their native configurations or in  
20 non-native configurations. Anti-idiotypic antibodies can also be generated. Many methods of making antibodies are known to persons of skill. The following discussion is presented as a general overview of the techniques available; however, one of skill will recognize that many variations upon the following methods are known.

#### 25 A) Antibody Production

A number of immunogens are used to produce antibodies specifically reactive with polypeptides according to the invention. Recombinant or synthetic polypeptides of 10 amino acids in length, or greater, selected from amino acid sub-sequences of SEQ ID NO 2 are the preferred polypeptide immunogen (antigen) for the production  
30 of monoclonal or polyclonal antibodies. In one class of preferred embodiments, and

immunogenic peptide conjugate is also included as an immunogen. Naturally occurring polypeptides are also used either in pure or impure form.

Recombinant polypeptides are expressed in eukaryotic or prokaryotic cells (as described below) and purified using standard techniques. The polypeptide, or a synthetic version thereof, is then injected into an animal capable of producing antibodies. Either monoclonal or polyclonal antibodies can be generated for subsequent use in immunoassays to measure the presence and quantity of the polypeptide.

10 Methods of producing polyclonal antibodies are known to those of skill in the art. In brief, an immunogen (antigen), preferably a purified polypeptide, a polypeptide coupled to an appropriate carrier (*e.g.*, GST, keyhole limpet hemocyanin, *etc.*), or a polypeptide incorporated into an immunization vector such as a recombinant vaccinia virus (*see*, U.S. Patent No. 4,722,848) is mixed with an adjuvant and animals  
15 are immunized with the mixture. The animal's immune response to the immunogen preparation is monitored by taking test bleeds and determining the titer of reactivity to the polypeptide of interest. When appropriately high titers of antibody to the immunogen are obtained, blood is collected from the animal and antisera are prepared. Further fractionation of the antisera to enrich for antibodies reactive to the polypeptide is performed where desired (*see, e.g.*, Coligan (1991) *Current Protocols in Im-*  
20 *munology* Wiley/Greene, NY; and Harlow and Lane (1989) *Antibodies: A Laboratory Manual* Cold Spring Harbor Press, NY).

Antibodies, including binding fragments and single chain recombinant versions thereof, against predetermined fragments of the present polypeptides are raised by immunizing animals, *e.g.*, with conjugates of the fragments with carrier proteins as described above. Typically, the immunogen of interest is a peptide of at least about 5 amino acids; more typically the peptide is 10 amino acids in length; preferably, the fragment is 15 amino acids in length and more preferably the fragment is 20 amino  
30 acids in length or greater. The peptides are typically coupled to a carrier protein

(e.g., as a fusion protein), or are recombinantly expressed in a immunization vector. Antigenic determinants on peptides to which antibodies bind are typically 3 to 10 amino acids in length.

- 5 Monoclonal antibodies are prepared from cells secreting the desired antibody. These antibodies are screened for binding to normal or modified polypeptides, or screened for agonistic or antagonistic activity, e.g., activity mediated through a *fused* protein. Specific monoclonal and polyclonal antibodies will usually bind with a  $K_D$  of at least about 0.1 mM, more usually at least about 50  $\mu$ M, and most preferably at least  
10 about 1  $\mu$ M or better.

- In some instances, it is desirable to prepare monoclonal antibodies from various mammalian hosts, such as mice, rodents, primates, humans, *etc.* Description of techniques for preparing such monoclonal antibodies are found in, e.g. Stites *et al.* (eds)  
15 *Basic and Clinical Immunology* (4th ed.) Lange Medical Publications, Los Altos, CA, and references cited therein; Harlow and Lane, *supra*; Goding (1986) *Monoclonal Antibodies: Principles and Practice* (2d ed.) Academic Press, New York, NY; and Kohler and Milstein (1975) *Nature* 256: 495-497. Summarized briefly, this method proceeds by injecting an animal with an immunogen. The animal is then sa-  
20 crificed and cells taken from its spleen, which are fused with myeloma cells. The result is a hybrid cell or "hybridoma" that is capable of reproducing *in vitro*. The population of hybridomas is then screened to isolate individual clones, each of which secrete a single antibody species to the immunogen. In this manner, the individual antibody species obtained are the products of immortalized and cloned single  
25 B cells from the immune animal generated in response to a specific site recognized on the immunogenic substance.

- Alternative methods of immortalization include transformation with Epstein Barr Virus, oncogenes, or retroviruses, or other methods known in the art. Colonies  
30 arising from single immortalized cells are screened for production of antibodies of

the desired specificity and affinity for the antigen, and yield of the monoclonal antibodies produced by such cells is enhanced by various techniques, including injection into the peritoneal cavity of a vertebrate (preferably mammalian) host. The polypeptides and antibodies of the present invention are used with or without modification, and include chimeric antibodies such as humanized murine antibodies.

Other suitable techniques involve selection of libraries of recombinant antibodies in phage or similar vectors (*see, e.g., Huse et al. (1989) Science 246: 1275-1281; and Ward, et al. (1989) Nature 341: 544-546; and Vaughan et al. (1996) Nature Biotechnology, 14: 309-314*).

Frequently, the polypeptides and antibodies will be labeled by joining, either covalently or non-covalently, a substance which provides for a detectable signal. A wide variety of labels, and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionucleotides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, chemiluminescent moieties, magnetic particles, and the like. Patents teaching the use of such labels include U.S. Patent Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241. Also recombinant immunoglobulins may be produced. See, Caballito, U.S. Patent No. 4,816,567; and Queen *et al.* (1989) *Proc. Nat'l Acad. Sci. USA* 86: 10029-10033.

The antibodies of this invention are also used for affinity chromatography in isolating *fused* polypeptides. Columns are prepared, *e.g.*, with the antibodies linked to a solid support, *e.g.*, particles, such as agarose, Sephadex, or the like, where a cell lysate is passed through the column, washed, and treated with increasing concentrations of a mild denaturant, whereby purified *fused* polypeptides are released.

The antibodies can be used to screen expression libraries for particular expression products such as normal or abnormal human *fused* protein. Usually the antibodies in

such a procedure are labeled with a moiety allowing easy detection of presence of antigen by antibody binding.

Antibodies raised against *fused* polypeptides can also be used to raise antiidiotypic antibodies. These are useful for detecting or diagnosing various pathological conditions related to the presence of the respective antigens.

B) Human or humanized (chimeric) antibody production.

The antibodies of this invention can also be administered to an organism (*e.g.*, a human patient) for therapeutic purposes. Antibodies administered to an organism other than the species in which they are raised are often immunogenic. Thus, for example, murine antibodies administered to a human often induce an immunologic response against the antibody (*e.g.*, the human anti-mouse antibody (HAMA) response) on multiple administrations. The immunogenic properties of the antibody are reduced by altering portions, or all, of the antibody into characteristically human sequences thereby producing chimeric or human antibodies, respectively.

i) Humanized (chimeric) antibodies.

Humanized (chimeric) antibodies are immunoglobulin molecules comprising a human and non-human portion. More specifically, the antigen combining region (or variable region) of a humanized chimeric antibody is derived from a non-human source (*e.g.*, murine) and the constant region of the chimeric antibody (which confers biological effector function to the immunoglobulin) is derived from a human source. The humanized chimeric antibody should have the antigen binding specificity of the non-human antibody molecule and the effector function conferred by the human antibody molecule. A large number of methods of generating chimeric antibodies are well known to those of skill in the art (*see, e.g.*, U.S. Patent Nos: 5,502,167, 5,500,362, 4,491,088, 5,482,856, 5,472,693, 5,354,847, 5,292,867, 5,231,026, 5,204,244, 5,202,238, 5,169,939, 5,081,235, 5,075,431, and 4,975,369).

In general, the procedures used to produce these chimeric antibodies consist of the following steps (the order of some steps may be interchanged): (a) identifying and cloning the correct gene segment encoding the antigen binding portion of the antibody molecule; this gene segment (known as the DVJ, variable, diversity and joining regions for heavy chains or VJ, variable, joining regions, for light chains (or simply as the V or Variable region) may be in either the cDNA or genomic form; (b) cloning the gene segments encoding the constant region or desired part thereof; (c) ligating the variable region to the constant region so that the complete chimeric antibody is encoded in a transcribable and translatable form; (d) ligating this construct into a vector containing a selectable marker and gene control regions such as promoters, enhancers and poly(A) addition signals; (e) amplifying this construct in a host cell (*e.g.*, bacteria; (f) introducing the DNA into eukaryotic cells (transfections) most often mammalian lymphocytes; and culturing the host cell under conditions suitable for expression of the chimeric antibody.

Antibodies of several distinct antigen binding specificities have been manipulated by these protocols to produce chimeric proteins (*e.g.*, anti-TNP: Boulianne *et al.* (1984) *Nature*, 312: 643; and anti-tumor antigens: Sahagan *et al.* (1986) *J. Immunol.*, 137: 1066). Likewise several different effector functions have been achieved by linking new sequences to those encoding the antigen binding region. Some of these include enzymes (Neuberger *et al.* (1984) *Nature* 312:604), immunoglobulin constant regions from another species and constant regions of another immunoglobulin chain (Sharon *et al.* (1984) *Nature* 309: 364; Tan *et al.*, (1985) *J. Immunol.* 135: 3565-3567).

In one preferred embodiment, a recombinant DNA vector is used to transfect a cell line that produces an anti-*fused* antibody. The novel recombinant DNA vector contains a "replacement gene" to replace all or a portion of the gene encoding the immunoglobulin constant region in the cell line (*e.g.*, a replacement gene may encode all or a portion of a constant region of a human immunoglobulin, a specific immu-

noglobulin class, or an enzyme, a toxin, a biologically active peptide, a growth factor, inhibitor, or a linker peptide to facilitate conjugation to a drug, toxin, or other molecule, *etc.*), and a "target sequence" which allows for targeted homologous recombination with immunoglobulin sequences within the antibody producing cell.

5

In another embodiment, a recombinant DNA vector is used to transfect a cell line that produces an antibody having a desired effector function, (*e.g.*, a constant region of a human immunoglobulin) in which case, the replacement gene contained in the recombinant vector may encode all or a portion of a region of an anti-*fused* antibody and the target sequence contained in the recombinant vector allows for homologous recombination and targeted gene modification within the antibody producing cell. In either embodiment, when only a portion of the variable or constant region is replaced, the resulting chimeric antibody may define the same antigen and/or have the same effector function yet be altered or improved so that the chimeric antibody may demonstrate a greater antigen specificity, greater affinity binding constant, increased effector function, or increased secretion and production by the transfected antibody producing cell line, *etc.*

10  
15

Regardless of the embodiment practiced, the processes of selection for integrated DNA (via a selectable marker), screening for chimeric antibody production, and cell cloning, can be used to obtain a clone of cells producing the chimeric antibody.

20

Thus, a piece of DNA which encodes a modification for a monoclonal antibody can be targeted directly to the site of the expressed immunoglobulin gene within a B-cell or hybridoma cell line. DNA constructs for any particular modification may be used to alter the protein product of any monoclonal cell line or hybridoma. Such a procedure circumvents the costly and time consuming task of cloning both heavy and light chain variable region genes from each B-cell clone expressing a useful antigen specificity. In addition to circumventing the process of cloning variable region genes, the level of expression of chimeric antibody should be higher when the gene is

25  
30

at its natural chromosomal location rather than at a random position. Detailed methods for preparation of chimeric (humanized) antibodies can be found in U.S. Patent 5,482,856.

5    ii) Human antibodies.

In another embodiment, this invention provides for fully human anti-*fused* antibodies. Human antibodies consist entirely of characteristically human polypeptide sequences. The human antibodies of this invention can be produced in using a wide variety of methods (*see, e.g.*, Larrick *et al.*, U.S. Pat. No 5,001,065, for review).

- 10    In one preferred embodiment, the human antibodies of the present invention are usually produced initially in trioma cells. Genes encoding the antibodies are then cloned and expressed in other cells, particularly, nonhuman mammalian cells.

The general approach for producing human antibodies by trioma technology has been described by Ostberg *et al.* (1983) *Hybridoma* 2: 361-367, Ostberg, U.S. Pat. No. 4,634,664, and Engelman *et al.* U.S. Pat. No. 4,634,666. The antibody-producing cell lines obtained by this method are called triomas because they are descended from three cells; two human and one mouse. Triomas have been found to produce antibody more stably than ordinary hybridomas made from human cells.

20    Preparation of trioma cells requires an initial fusion of a mouse myeloma cell line with unimmunized human peripheral B lymphocytes. This fusion generates a xenogenic hybrid cell containing both human and mouse chromosomes (*see*, Engelman, *supra.*). Xenogenic cells that have lost the capacity to secrete antibodies are selected. Preferably, a xenogenic cell is selected that is resistant to 8-azaguanine. Cells possessing resistance to 8-azaguanine are unable to propagate on hypoxanthine-aminopterin-thymidine (HAT) or azaserine-hypoxanthine (AH) media.

30    The capacity to secrete antibodies is conferred by a further fusion between the xenogenic cell and B-lymphocytes immunized against a polypeptide according to the

invention or an epitope thereof. The B-lymphocytes are obtained from the spleen, blood or lymph nodes of human donor. If antibodies against a specific antigen or epitope are desired, it is preferable to use that antigen or epitope thereof as the immunogen rather than *fused* polypeptide. Alternatively, B-lymphocytes are obtained  
5 from an unimmunized individual and stimulated with the present polypeptide, or an epitope thereof, *in vitro*. In a further variation, B-lymphocytes are obtained from an infected, or otherwise immunized individual, and then hyperimmunized by exposure to a *fused* polypeptide for about seven to fourteen days, *in vitro*.

The immunized B-lymphocytes prepared by one of the above procedures are fused  
10 with a xenogenic hybrid cell by well known methods. For example, the cells are treated with 40-50% polyethylene glycol of MW 1000-4000, at about 37°C for about 5-10 min. Cells are separated from the fusion mixture and propagated in media selective for the desired hybrids. When the xenogenic hybrid cell is resistant to 8-azaguanine, immortalized trioma cells are conveniently selected by successive pas-  
15 sage of cells on HAT or AH medium. Other selective procedures are, of course, possible depending on the nature of the cells used in fusion. Clones secreting antibodies having the required binding specificity are identified by assaying the trioma culture medium for the ability to bind to the present polypeptide or an epitope thereof. Triomas producing human antibodies having the desired specificity are subcloned by  
20 the limiting dilution technique and grown *in vitro* in culture medium, or are injected into selected host animals and grown *in vitro*.

The trioma cell lines obtained are then tested for the ability to bind a polypeptide or an epitope thereof. Antibodies are separated from the resulting culture medium or  
25 body fluids by conventional antibody-fractionation procedures, such as ammonium sulfate precipitation, DEAE cellulose chromatography and affinity chromatography.

Although triomas are genetically stable they do not produce antibodies at very high levels. Expression levels can be increased by cloning antibodies genes from the tri-  
30 oma into one or more expression vectors, and transforming the vector into a cell

line, such as the cell lines typically used for expression of recombinant or humanized immunoglobulins. As well as increasing yield of antibody, this strategy offers the additional advantage that immunoglobulins are obtained from a cell line that does not have a human component, and does not therefore need to be subjected to the especially extensive viral screening required for human cell lines.

The genes encoding the heavy and light chains of immunoglobulins secreted by trioma cell lines are cloned according to methods, including the polymerase chain reaction, known in the art (*see, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor, N.Y., 1989; Berger & Kimmel, *Methods in Enzymology*, Vol. 152: *Guide to Molecular Cloning Techniques*, Academic Press, Inc., San Diego, Calif., 1987; Co *et al.* (1992) *J. Immunol.*, 148: 1149). For example, genes encoding heavy and light chains are cloned from a trioma's genomic DNA or cDNA produced by reverse transcription of the trioma's RNA. Cloning is accomplished by conventional techniques including the use of PCR primers that hybridize to the sequences flanking or overlapping the genes, or segments of genes, to be cloned.

Typically, recombinant constructs comprise DNA segments encoding a complete human immunoglobulin heavy chain and/or a complete human immunoglobulin light chain of an immunoglobulin expressed by a trioma cell line. Alternatively, DNA segments encoding only a portion of the primary antibody genes are produced, which portions possess binding and/or effector activities. Other recombinant constructs contain segments of trioma cell line immunoglobulin genes fused to segments of other immunoglobulin genes, particularly segments of other human constant region sequences (heavy and/or light chain). Human constant region sequences can be selected from various reference sources, including but not limited to those listed in Kabat *et al.* (1987) *Sequences of Proteins of Immunological Interest*, U.S. Department of Health and Human Services.

In addition to the DNA segments encoding anti-*fused* immunoglobulins or fragments thereof, other substantially homologous modified immunoglobulins can be readily designed and manufactured utilizing various recombinant DNA techniques known to those skilled in the art such as site-directed mutagenesis (see Gillman & Smith (1979) *Gene*, 8: 81-97; Roberts *et al.* (1987) *Nature* 328: 731-734). Such modified segments will usually retain antigen binding capacity and/or effector function. Moreover, the modified segments are usually not so far changed from the original trioma genomic sequences to prevent hybridization to these sequences under stringent conditions. Because, like many genes, immunoglobulin genes contain separate functional regions, each having one or more distinct biological activities, the genes may be fused to functional regions from other genes to produce fusion proteins (e.g., immunotoxins) having novel properties or novel combinations of properties.

The recombinant polynucleotide constructs will typically include an expression control sequence operably linked to the coding sequences, including naturally associated or heterologous promoter regions. Preferably, the expression control sequences will be eukaryotic promoter systems in vectors capable of transforming or transfecting eukaryotic host cells. Once the vector has been incorporated into the appropriate host, the host is maintained under conditions suitable for high level expression of the nucleotide sequences, and the collection and purification of the human anti-*fused* immunoglobulins.

These expression vectors are typically replicable in the host organisms either as episomes or as an integral part of the host chromosomal DNA. Commonly, expression vectors will contain selection markers, e.g. ampicillin-resistance or hygromycin-resistance, to permit detection of those cells transformed with the desired DNA sequences.

In general, prokaryotes can be used for cloning the DNA sequences encoding a human anti-*fused* immunoglobulin chain. *E. coli* is one prokaryotic host particularly

useful for cloning the DNA sequences of the present invention. Microbes, such as yeast are also useful for expression. *Saccharomyces* is a preferred yeast host, with suitable vectors having expression control sequences, an origin of replication, termination sequences and the like as desired. Typical promoters include 3-

- 5 phosphoglycerate kinase and other glycolytic enzymes. Inducible yeast promoters include, among others, promoters from alcohol dehydrogenase 2, isocytochrome C, and enzymes responsible for maltose and galactose utilization.

- Mammalian cells are a particularly preferred host for expressing nucleotide segments encoding immunoglobulins or fragments thereof (*see, e.g.* Winnacker, *From Genes to Clones*, VCH Publishers, N.Y., 1987). A number of suitable host cell lines capable of secreting intact heterologous proteins have been developed in the art, and include CHO cell lines, various COS cell lines, HeLa cells, L cells and myeloma cell lines. Preferably, the cells are nonhuman. Expression vectors for these cells can include expression control sequences, such as an origin of replication, a promoter, an enhancer (Queen *et al.* (1986) *Immunol. Rev.* 89:49), and necessary processing information sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites, and transcriptional terminator sequences. Preferred expression control sequences are promoters derived from endogenous genes, cytomegalovirus, SV40, adenovirus, bovine papillomavirus, and the like (*see, e.g.*, Co *et al.* (1992) *J. Immunol.* 1458: 1149).
- 10  
15  
20

- The vectors containing the DNA segments of interest can be transferred into the host cell by well-known methods, depending on the type of cellular host. For example, calcium chloride transfection is commonly utilized for prokaryotic cells, whereas calcium phosphate treatment, electroporation, lipofection, biolistics or viral-based transfection may be used for other cellular hosts. Other methods used to transform mammalian cells include the use of polybrene, protoplast fusion, liposomes, electroporation, and microinjection (*see, generally, Sambrook et al., supra*).
- 25

Once expressed, human anti-*fused* immunoglobulins of the invention can be purified according to standard procedures of the art, including HPLC purification, fraction column chromatography, gel electrophoresis and the like (see, generally, Scopes, *Protein Purification*, Springer-Verlag, NY, 1982). Detailed protocols for the production of human antibodies can be found in U.S. Patent 5,506,132.

Other approaches *in vitro* immunization of human blood. In this approach, human blood lymphocytes capable of producing human antibodies are produced. Human peripheral blood is collected from the patient and is treated to recover mononuclear cells. The suppressor T-cells then are removed and remaining cells are suspended in a tissue culture medium to which is added the antigen and autologous serum and, preferably, a nonspecific lymphocyte activator. The cells then are incubated for a period of time so that they produce the specific antibody desired. The cells then can be fused to human myeloma cells to immortalize the cell line, thereby to permit continuous production of antibody (see U.S. Patent 4,716,111).

In another approach, mouse-human hybridomas which produces human anti-*fused* are prepared (see, e.g. 5,506,132). Other approaches include immunization of murines transformed to express human immunoglobulin genes, and phage display screening (Vaughan *et al. Supra*).

#### IV. Expression of *fused* polypeptides.

##### A) *De novo* chemical synthesis.

The present proteins or subsequences thereof may be synthesized using standard chemical peptide synthesis techniques. Where the desired subsequences are relatively short (e.g., when a particular antigenic determinant is desired) the molecule may be synthesized as a single contiguous polypeptide. Where larger molecules are desired, subsequences can be synthesized separately (in one or more units) and then fused by condensation of the amino terminus of one molecule with the carboxyl terminus of the other molecule thereby forming a peptide bond.

Solid phase synthesis in which the C-terminal amino acid of the sequence is attached to an insoluble support followed by sequential addition of the remaining amino acids in the sequence is the preferred method for the chemical synthesis of the polypeptides of this invention. Techniques for solid phase synthesis are described by Barany and Merrifield, *Solid-Phase Peptide Synthesis*; pp. 3-284 in *The Peptides: Analysis, Synthesis, Biology. Vol. w: Special Methods in peptide Synthesis, Part A.*, Merrifield, et al. *J. Am. Chem. Soc.*, 85: 2149-2156 (1963), and Stewart et al., *Solid Phase Peptide Synthesis, 2nd ed.* Pierce Chem. Co., Rockford, Ill. (1984).

10 B. Recombinant expression.

In a preferred embodiment, the present proteins or subsequences thereof are synthesized using recombinant DNA methodology. Generally this involves creating a DNA sequence that encodes the fusion protein, placing the DNA in an expression cassette under the control of a particular promoter, expressing the protein in a host, 15 isolating the expressed protein and, if required, renaturing the protein.

DNA encoding the present proteins or subsequences of this invention may be prepared by any suitable method as described above, including, for example, cloning and restriction of appropriate sequences or direct chemical synthesis by methods such as 20 the phosphotriester method of Narang et al. *Meth. Enzymol.* 68: 90-99 (1979); the phosphodiester method of Brown et al., *Meth Enzymol.* 68: 109-151 (1979); the diethylphosphoramidite method of Beaucage et al., *Tetra. Lett.*, 22: 1859-1862 (1981); and the solid support method of U.S. Patent No. 4,458,066.

25 Chemical synthesis produces a single stranded oligonucleotide. This may be converted into double stranded DNA by hybridization with a complementary sequence, or by polymerization with a DNA polymerase using the single strand as a template. One of skill would recognize that while chemical synthesis of DNA is limited to sequences of about 100 bases, longer sequences may be obtained by the ligation of 30 shorter sequences.

Alternatively, subsequences may be cloned and the appropriate subsequences cleaved using appropriate restriction enzymes. The fragments may then be ligated to produce the desired DNA sequence.

5

In one embodiment, proteins of this invention may be cloned using DNA amplification methods such as polymerase chain reaction (PCR). Thus, for example, the nucleic acid sequence or subsequence is PCR amplified, using a sense primer containing one restriction site (*e.g.*, NdeI) and an antisense primer containing another restriction site (*e.g.*, HindIII). This will produce a nucleic acid encoding the desired sequence or subsequence and having terminal restriction sites. This nucleic acid can then be easily ligated into a vector containing a nucleic acid encoding the second molecule and having the appropriate corresponding restriction sites. Suitable PCR primers can be determined by one of skill in the art using the Sequence information provided in SEQ ID No:1. Appropriate restriction sites can also be added to the nucleic acid encoding the protein or protein subsequence by site-directed mutagenesis. The plasmid containing the sequence or subsequence is cleaved with the appropriate restriction endonuclease and then ligated into the vector encoding the second molecule according to standard methods.

20

The nucleic acid sequences encoding *fused* proteins or protein subsequences may be expressed in a variety of host cells, including *E. coli*, other bacterial hosts, yeast, and various higher eukaryotic cells such as the COS, CHO and HeLa cells lines and myeloma cell lines. As the present proteins are typically found in eukaryotes, a eukaryote host is preferred. The recombinant protein gene will be operably linked to appropriate expression control sequences for each host. For *E. coli* this includes a promoter such as the T7, trp, or lambda promoters, a ribosome binding site and preferably a transcription termination signal. For eukaryotic cells, the control sequences will include a promoter and preferably an enhancer derived from immu-

25

noglobulin genes, SV40, cytomegalovirus, *etc.*, and a polyadenylation sequence, and may include splice donor and acceptor sequences.

The plasmids of the invention can be transferred into the chosen host cell by well-known methods such as calcium chloride transformation for *E. coli* and calcium phosphate treatment or electroporation for mammalian cells. Cells transformed by the plasmids can be selected by resistance to antibiotics conferred by genes contained on the plasmids, such as the amp, gpt, neo and hyg genes.

Once expressed, the recombinant proteins according to the invention can be purified according to standard procedures of the art, including ammonium sulfate precipitation, affinity columns, column chromatography, gel electrophoresis and the like (*see, generally, R. Scopes, Protein Purification, Springer-Verlag, N.Y. (1982), Deutscher, Methods in Enzymology Vol. 183: Guide to Protein Purification., Academic Press, Inc. N.Y. (1990)*). Substantially pure compositions of at least about 90 to 95% homogeneity are preferred, and 98 to 99% or more homogeneity are most preferred. Once purified, partially or to homogeneity as desired, the polypeptides may then be used (*e.g., immunogens for antibody production*).

One of skill in the art would recognize that after chemical synthesis, biological expression, or purification, the present protein(s) may possess a conformation substantially different than the native conformations of the constituent polypeptides. In this case, it may be necessary to denature and reduce the polypeptide and then to cause the polypeptide to re-fold into the preferred conformation. Methods of reducing and denaturing proteins and inducing re-folding are well known to those of skill in the art (*See, Debinski et al. (1993) J. Biol. Chem., 268: 14065-14070; Kreitman and Pastan (1993) Bioconjug. Chem., 4: 581-585; and Buchner, et al., (1992) Anal. Biochem., 205: 263-270*). Debinski *et al.*, for example, describe the denaturation and reduction of inclusion body proteins in guanidine-DTE. The protein is then refolded in a redox buffer containing oxidized glutathione and L-arginine.

One of skill would recognize that modifications can be made to the *fused* proteins without diminishing their biological activity. Some modifications may be made to facilitate the cloning, expression, or incorporation of the targeting molecule into a fusion protein. Such modifications are well known to those of skill in the art and include, for example, a methionine added at the amino terminus to provide an initiation site, or additional amino acids (*e.g.*, poly His) placed on either terminus to create conveniently located restriction sites or termination codons or purification sequences.

#### V. Detection of *fused*

As indicated above, abnormal (*e.g.*, altered or deficient) expression of the human *fused* gene is believed to be a causal factor in the development of several different conditions, such as cancers.

Thus, it is desirable to determine the presence or absence, or quantify, the expression of *fused* polypeptides of the nucleic acids encoding the *fused* polypeptides. This may be accomplished by assaying the gene product; *fused* polypeptides themselves, or alternatively, by assaying the nucleic acids (DNA or mRNA) that encode the *fused* polypeptides. In particular, it is desirable to determine whether *fused* expression is present, absent, or abnormal (*e.g.*, because of an abnormal gene product or because of abnormal expression levels as, for example, with a hemizygous gene). Particularly, where it is desired to determine a heritable propensity for abnormal *fused* gene expression, it is preferred to assay the host DNA for abnormal *fused* genes or gene transcripts (mRNAs).

#### A) Sample Collection and Processing

The *fused* gene or gene product (*i.e.*, mRNA or polypeptide) is preferably detected and/or quantified in a biological sample. As used herein, a biological sample is a sample of biological tissue or fluid that, in a healthy and/or pathological state, con-

tains a *fused* nucleic acid or polypeptide. Such samples include, but are not limited to, sputum, amniotic fluid, blood, blood cells (*e.g.*, white cells), tissue or fine needle biopsy samples, urine, peritoneal fluid, and pleural fluid, or cells therefrom. Biological samples may also include sections of tissues such as frozen sections taken for histological purposes. Although the sample is typically taken from a human patient, the assays can be used to detect *fused* genes or gene products in samples from any mammal, such as dogs, cats, sheep, cattle, and pigs.

The sample may be pretreated as necessary by dilution in a appropriate buffer solution or concentrated, if desired. Any of a number of standard aqueous buffer solutions, employing one of a variety of buffers, such as phosphate, Tris, or the like, at physiological pH can be used.

#### B) Nucleic acid assays.

In one embodiment, this invention provides for methods of detecting and/or quantifying human *fused* expression by assaying the underlying *fused* gene (or a fragment thereof) or by assaying the *fused* gene transcript (mRNA). The assay can be for the presence or absence of the normal gene or gene product, for the presence or absence of an abnormal gene or gene product, or quantification of the transcription levels of normal or abnormal *fused* gene product.

##### i) Nucleic acid sample.

In a preferred embodiment, nucleic acid assays are performed with a sample of nucleic acid isolated from the organism to be tested. In the simplest embodiment, such a nucleic acid sample is the total mRNA isolated from a biological sample. The nucleic acid (*e.g.*, either genomic DNA or mRNA) may be isolated from the sample according to any of a number of methods well known to those of skill in the art. One of skill will appreciate that where alterations in the copy number of the *fused* gene are to be detected genomic DNA is preferably isolated. Conversely, where ex-

pression levels of a gene or genes are to be detected, preferably RNA (mRNA) is isolated.

Methods of isolating total DNA or mRNA are well known to those of skill in the art.

- 5 For example, methods of isolation and purification of nucleic acids are described in detail in Chapter 3 of *Laboratory Techniques in Biochemistry and Molecular Biology: Hybridization With Nucleic Acid Probes, part I. Theory and Nucleic Acid Preparation*, P. Tijssen, ed. Elsevier, N.Y. (1993) and Chapter 3 of *Laboratory Techniques in Biochemistry and Molecular Biology: Hybridization With Nucleic Acid*  
10 *Probes, Part I. Theory and Nucleic Acid Preparation*. P. Tijssen ed. Elsevier, N.Y. (1993)).

- In a preferred embodiment, the total nucleic acid is isolated from a given sample using, for example, an acid guanidinium-phenol-chloroform extraction method and poly A<sup>+</sup> mRNA is isolated by oligo dT column chromatography or by using (dT)<sub>n</sub>  
15 magnetic beads (see, e.g., Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual* 2nd ed.), Vols.1-3, Cold Spring Harbor Laboratory, (1989), or *Current Protocols in Molecular Biology*, F. Ausubel *et al.*, ed. Greene Publishing and Wiley-Interscience, New York (1987)).

- 20 Frequently, it is desirable to amplify the nucleic acid sample prior to hybridization. One of skill in the art will appreciate that whatever amplification method is used, if a quantitative result is desired, care must be taken to use a method that maintains or controls for the relative frequencies of the amplified nucleic acids.

- 25 Methods of "quantitative" amplification are well known to those of skill in the art. For example, quantitative PCR involves simultaneously co-amplifying a known quantity of a control sequence using the same primers. This provides an internal standard that may be used to calibrate the PCR reaction. The high density array may then include probes specific to the internal standard for quantification of the amplified  
30 nucleic acid.

One preferred internal standard is a synthetic AW106 cRNA. The AW106 cRNA is combined with RNA isolated from the sample according to standard techniques known to those of skill in the art. The RNA is then reverse transcribed using a reverse transcriptase to provide copy DNA. The cDNA sequences are then amplified (e.g., by PCR) using labeled primers. The amplification products are separated, typically by electrophoresis, and the amount of radioactivity (proportional to the amount of amplified product) is determined. The amount of mRNA in the sample is then calculated by comparison with the signal produced by the known AW106 RNA standard. Detailed protocols for quantitative PCR are provided in *PCR Protocols, A guide to Methods and Applications*, Innis *et al.*, Academic Press, Inc. N.Y., (1990). Other suitable amplification methods include, but are not limited to polymerase chain reaction (PCR) (Innis *et al.*, (1990) *PCR Protocols. A guide to Methods and Application*. Academic Press, Inc. San Diego), ligase chain reaction (LCR) (see Wu and Wallace (1989) *Genomics* 4: 560, Landegren *et al.* (1988) *Science* 241: 1077, and Barringer *et al.* (1990) *Gene* 89: 117, transcription amplification (Kwoh *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86: 1173), and self-sustained sequence replication (Guatelli *et al.* (1990) *Proc. Nat. Acad. Sci. USA* 87: 1874).

20 ii) Hybridization assays.

A variety of methods for specific DNA and RNA measurement using nucleic acid hybridization techniques are known to those of skill in the art (see Sambrook *et al. Supra*). For example, one method for evaluating the presence, absence, or quantity of DNA encoding *fused* proteins in a sample involves a Southern transfer. Briefly, the digested genomic DNA is run on agarose slab gels in buffer and transferred to membranes.

Hybridization is carried out using the nucleic acid probes specific for the target *fused* sequence or subsequence. Nucleic acid probes are designed based on the nucleic acid sequences encoding *fused* proteins (see SEQ ID NO: 2). The probes can be full

length of the nucleic acid sequence encoding the *fused* protein. Shorter probes are empirically tested for specificity. Preferably nucleic acid probes are 20 bases or longer in length. (See Sambrook *et al.* For methods of selecting nucleic acid probe sequences for use in nucleic acid hybridization.) Visualization of the hybridized portions allows the qualitative determination of the presence or absence of DNA encoding *fused* proteins.

Similarly, a Northern transfer may be used for the detection of mRNA encoding *fused* proteins. In brief, the mRNA is isolated from a given cell sample using, for example, and acid guanidinium-phenol-chloroform extraction method. The mRNA is then electrophoresed to separate the mRNA species and the mRNA is transferred from the gel to a nitrocellulose membrane. As with the Southern blots, labeled probes are used to identify the presence or absence of *fused* proteins.

A variety of nucleic acid hybridization formats are known to those skilled in the art. For example, common formats include sandwich assays and competition or displacement assays. Hybridization techniques are generally described in "*Nucleic Acid Hybridization, A Practical Approach*," Ed. Hames, B.D. and Higgins, S.J., IRL Press, (1985); Gall and Pardue *Proc. Natl. Acad. Sci. U.S.A.* 63: 378-383 (1969); and John *et al. Nature* 223: 582-587 (1969).

For example, sandwich assays are commercially useful hybridization assays for detecting or isolating nucleic acid sequences. Such assays utilize a "capture" nucleic acid covalently immobilized to a solid support and a labeled "signal" nucleic acid in solution. The clinical sample will provide the target nucleic acid. The "capture" nucleic acid and "signal" nucleic acid probe hybridize with the target nucleic acid to form a "sandwich" hybridization complex. To be effective, the signal nucleic acid cannot hybridize with the capture nucleic acid:

Typically, labeled signal nucleic acids are used to detect hybridization. Complementary nucleic acids or signal nucleic acids may be labeled by any one of several methods typically used to detect the presence of hybridized polynucleotides. The most common method of detection is the use of autoradiography with  $^3\text{H}$ ,  $^{125}\text{I}$ ,  $^{35}\text{S}$ ,  $^{14}\text{C}$ , or  $^{32}\text{P}$ -labelled probes or the like. Other labels include ligands which bind to labeled antibodies, fluorophores, chemiluminescent agents, enzymes, and antibodies which can serve as specific binding pair members for a labeled ligand.

Detection of a hybridization complex may require the binding of a signal generating complex to a duplex of target and probe polynucleotides or nucleic acids. Typically, such binding occurs through ligand and anti-ligand interactions as between a ligand-conjugated probe and an anti-ligand conjugated with a signal.

The label may also allow indirect detection of the hybridization complex. For example, where the label is a hapten or antigen, the sample can be detected by using antibodies. In these systems, a signal is generated by attaching fluorescent or enzyme molecules to the antibodies or, in some cases, by attachment to a radioactive label. (Tijssen, P., "Practice and Theory of Enzyme Immunoassays," *Laboratory Techniques in Biochemistry and Molecular Biology*, Burdon, R.H., van Knippenberg, P.H., Eds., Elsevier (1985), pp. 9-20.).

The sensitivity of the hybridization assays may be enhanced through use of a nucleic acid amplification system which multiplies the target nucleic acid being detected. Examples of such systems include the polymerase chain reaction (PCR) system and the ligase chain reaction (LCR) system. Other methods recently described in the art are the nucleic acid sequence based amplification (NASBA<sup>TM</sup>, Cangene, Mississauga, Ontario) and Q Beta Replicase systems.

An alternative means for determining the level of expression of a gene encoding a fused protein is *in situ* hybridization. *In situ* hybridization assays are well known and are generally described in Angerer, *et al.*, *Methods Enzymol.*, 152: 649-660

(1987). In an *in situ* hybridization assay, cells or tissue specimens are fixed to a solid support, typically a glass slide. If DNA is to be probed, the cells are denatured with heat or alkali. The cells are then contacted with a hybridization solution at a moderate temperature to permit annealing of labeled probes specific to *fused* proteins. The probes are preferably labeled with radioisotopes of fluorescent reporters.

iii) Amplification based assays.

In another embodiment, the *fused* gene or gene product can be detected (assayed) using an amplification based assay. In an amplification based assay, all or part of the *fused* gene or transcript (*e.g.*, mRNA or cDNA) is amplified and the amplification product is then detected. Where there is no underlying gene or gene product to act as a template amplification is non-specific or non-existent and there is no single amplification product. Where the underlying gene or gene product is present, the target sequence is amplified providing an indication of the presence, absence, or quantity of the underlying gene or mRNA.

Amplification-based assays are well known to those of skill in the art (*see, e.g.*, Innis, *supra.*). The cDNA sequence provided for the *fused* gene is sufficient to enable one of skill to routinely select primers to amplify any portion of the gene.

Amplification primers can be selected to provide amplification products that span specific deletions, truncations, and insertions, thereby facilitating the detection of specific abnormalities.

iv) Specific detection of abnormalities (*e.g.*, mutations).

Abnormal *fused* genes or gene products are characterized by premature stop codons, deletions, insertions or change of particular amino acids. Premature stop codons and deletions can be detected by decreased size of the gene or gene product (mRNA transcript or cDNA). Similarly, insertions can be detected by increased size of the

gene or gene product. Alternatively, mutations can be determined by sequencing of the gene or gene product according to standard methods.

In addition, amplification assays and hybridization probes can be selected to specifically target particular abnormalities. For example, where the abnormality is a deletion, nucleic acid probes or amplification primers can be selected that specifically hybridize to or amplify, respectively, the nucleic acid sequence that is deleted in the abnormal gene. The probe will fail to hybridize, or the amplification reaction will fail to provide specific amplification, to abnormal versions of the *fused* nucleic acids which have the deletion. Alternatively, the probe or amplification reaction can be designed to span the entire deletion or either end of the deletion (deletion junction). Similarly, probes and amplification primers can be selected that specifically target point mutations or insertions. Methods for detecting specific mutations were described in, for example, US Patent No. 5,512,441. In the case of PCR, amplification primers can be designed to hybridize to a portion of the *fused* gene but the terminal nucleotide at the 3' end of the primer can be used to discriminate between the mutant and wild-type forms of *fused* gene. If the terminal base matches the point mutation or the wild-type sequence, polymerase dependent extension can proceed and an amplification product is detected. This method for detecting point mutations or polymorphisms was described in detail by Sommer *et al.*, (1989) *Mayo Clin. Proc.* 64:1361-1372. By using appropriate controls, one can develop a kit having both positive and negative amplification products. The products can be detected using specific probes or by simply detecting their presence or absence. A variation of the PCR method uses LCR where the point of discrimination, *i.e.*, either the point mutation or the wild-type bases fall between the LCR oligonucleotides. The ligation of the oligonucleotides becomes the means for discriminating between the mutant and wild-type forms of the *fused* gene.

A variety of automated solid-phase detection techniques are also appropriate for detecting the presence or absence of mutations in the *fused* gene. For instance, very

large scale immobilized polymer arrays (VLSIPS<sup>TM</sup>), available from Affymetrix, Inc. In Santa Clara, CA are used for the detection of nucleic acids having specific sequences of interest. See, Fodor *et al.* (1991) *Science*, 251: 767-777; Sheldon *et al.* (1993) *Clinical Chemistry* 39(4): 718-719, and Kozal *et al.* (1996) *Natural Medicine* 2(7): 753-759. For example, oligonucleotides that hybridize to all known *fused* mutations can be synthesized on a DNA chip (such chips are available from Affymetrix) and the nucleic acids from samples hybridized to the chip for simultaneous analysis of the sample nucleic acid for the presence or absence of any of the known *fused* mutations. Protocols for detecting mutations are also described in, for example, Tijssen (1993) *Laboratory Techniques in biochemistry and molecular biology—hybridization with nucleic acid probes parts I and II*, Elsevier, new York, and Choo (ed) (1994) *Methods In Molecular Biology* Volume 33-*In situ Hybridization Protocols*, Humana Press Inc., New Jersey (see also, other books in the *Methods in Molecular Biology* series).

#### v. Detection of expression levels.

Where it is desired to quantify the transcription level (and thereby expression) of a normal or mutated *fused* genes in a sample, the nucleic acid sample is one in which the concentration of the mRNA transcript(s) of the *fused* gene, or the concentration of the nucleic acids derived from the mRNA transcript(s), is proportional to the transcription level (and therefore expression level) of that gene. Similarly, it is preferred that the hybridization signal intensity be proportional to the amount of hybridized nucleic acid. While it is preferred that the proportionality be relatively strict (e.g., a doubling in transcription rate results in a doubling in mRNA transcript in the sample nucleic acid pool and a doubling in hybridization signal), one of skill will appreciate that the proportionality can be more relaxed and even non-linear. Thus, for example, an assay where a 5 fold difference in concentration of the target mRNA results in a 3 to 6 fold difference in hybridization intensity is sufficient for most purposes. Where more precise quantification is required appropriate controls can be run to correct for variations introduced in sample preparation and hybridization as described herein. In

addition, serial dilutions of "standard" target mRNAs can be used to prepare calibration curves according to methods well known to those of skill in the art. Of course, where simple detection of the presence or absence of a transcrip is desired, no elaborate control or calibration is required.

5

### C) Polypeptide assays.

The expression of the human *fused* gene can also be detected and/or quantified by detecting or quantifying the expressed *fused* polypeptide. The *fused* polypeptides can be detected and quantified by any of a number of means well known to those of skill in the art. These may include analytic biochemical methods such as electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), hyperdiffusion chromatography, and the like, or various immunological methods such as fluid or gel precipitin reactions, immunodiffusion (single or double), immunoelectrophoresis, radioimmunoassay(RIA), enzyme-linked immunosorbent assays (ELISAs), immunofluorescent assays, Western blotting, and the like.

10

In a particularly preferred embodiment, the *fused* polypeptides are detected in an electrophoretic protein separation, more preferably in a two-dimensional electrophoresis, while in a most preferred embodiment, the *fused* polypeptides are detected using an immunoassay.

15

As used herein, an immunoassay is an assay that utilizes an antibody to specifically bind to the analyte (*fused* polypeptide). The immunoassay is thus characterized by detection of specific binding of a *fused* polypeptide to an anti-*fused* antibody as opposed to the use of other physical or chemical properties to isolate, target, and quantify the analyte.

20

### 1) Electrophoretic Assays.

As indicated above, the presence or absence of *fused* polypeptides in a biological sample can be determined using electrophoretic methods. Means of detecting pro-

25

teins using electrophoretic techniques are well known to those of skill in the art (*see generally*, R. Scopes (1982) *Protein Purification*, Springer-Verlag, N.Y.; Deutscher, (1990) *Methods in Enzymology Vol. 182: Guide to Protein Purification.*, Academic Press, Inc., N.Y.).

5

## 2) Immunological Binding Assays.

In a preferred embodiment, the *fused* polypeptides are detected and/or quantified using any of a number of well recognized immunological binding assays (*see, e.g.*, U.S. Patent 4,366,241; 4,376,110; 4,517,288; and 4,837,168). For a review of the  
10 general immunoassays, see also *Methods in Cell Biology Volume 37: antibodies in Cell Biology*, Asain, ed. Academic Press, Inc. New York (1993); *Basic and Clinical Immunology* 7th Edition, Stites & Terr, eds. (1991). Immunological binding assays (or immunoassays) typically utilize a "capture agent" to specifically bind to and often immobilize the analyte (in this case *fused* polypeptide or subsequence). The  
15 capture agent is a moiety that specifically binds to the analyte. In a preferred embodiment, the capture agent is an antibody that specifically binds *fused* polypeptide(s). The antibody (anti-*fused*) may be produced by any of a number of means well known to those of skill in the art as described above in Section III(A).

20 Immunoassays also often utilize a labeling agent to specifically bind to and label the binding complex formed by the capture agent and the analyte. The labeling agent may itself be one of the moieties comprising the antibody/analyte complex. Thus, the labeling agent may be a labeled *fused* polypeptide or a labeled anti-*fused* antibody. Alternatively, the labeling agent may be a third moiety, such as another antibody,  
25 dy, that specifically binds to the antibody/*fused* complex.

In a preferred embodiment, the labeling agent is a second human *fused* antibody bearing a label. Alternatively, the second *fused* antibody may lack a label, but it may, in turn, be bound by a labeled third antibody specific to antibodies of the species  
30 from which the second antibody is derived. The second can be modified with a de-

tectable moiety, such as biotin, to which a third labeled molecule can specifically bind, such as enzyme labeled streptavidin.

Other proteins capable of specifically binding immunoglobulin constant regions,  
5 such as protein A or protein G, may also be used as the label agent. The protein are normal constituents of the cell walls of streptococcal bacteria. They exhibit a strong non-immunogenic reactivity with immunoglobulin constant regions from a variety of species (*see, generally Kronval, et al. (1973) J. Immunol., 111: 1401-1406, and Akerstrom, et al. (1985) J. Immunol., 135:2589-2542).*

10

Throughout the assays, incubation and/or washing steps may be required after each combination of reagents. Incubation steps can vary from about 5 seconds to several hours, preferably from about 5 minutes to about 24 hours. However, the incubation time will depend upon the assay format, analyte, volume of solution, concentrations,  
15 and the like. Usually, the assays will be carried out at ambient temperature, although they can be conducted over a range of temperatures, such as 10°C to 40°C.

#### a) Non-Competitive Assay Formats.

Immunoassays for detecting *fused* polypeptide may be either competitive or non-  
20 competitive. Noncompetitive immunoassays are assays in which the amount of captured analyte (in this case *fused*) is directly measured. In one preferred "sandwich" assay, for example, the capture agent (anti-*fused* antibodies) can be bound directly to a solid substrate where they are immobilized. These immobilized antibodies then capture *fused* present in the test sample. The *fused* thus immobilized in  
25 then bound by a labeling agent, such as a second human *fused* antibody bearing a label. Alternatively, the second *fused* antibody may lack a label, but it may, in turn, be bound by a labeled third antibody specific to antibodies of the species from which the second antibody is derived. The second can be modified with a detectable moiety, such as biotin, to which a third labeled molecule can specifically bind, such  
30 as enzyme-labeled streptavidin.

b) Competitive assay formats.

In competitive assays, the amount of analyte (*fused*) present in the sample is measured indirectly by measuring the amount of an added (exogenous) analyte (*fused*)  
5 displaced (or competed away) from a capture agent (anti-*fused* antibody) by the analyte present in the sample. In one competitive assay, a known amount of, in this case, *fused* is added to the sample and the sample is then contacted with a capture agent, in this case an antibody that specifically binds *fused*. The amount of *fused* bound to the antibody is inversely proportional to the concentration of *fused* present in  
10 the sample.

In a particularly preferred embodiment, the antibody is immobilized on a solid substrate. The amount of *fused* bound to the antibody may be determined either by measuring the amount of *fused* present in a *fused*/antibody complex, or alternatively by  
15 measuring the amount of remaining uncomplexed *fused*. The amount of *fused* may be detected by providing a labeled *fused* molecule.

A hapten inhibition assay is another preferred competitive assay. In this assay a known analyte, in this case *fused*, is immobilized on a solid substrate. A known amount of anti-*fused* antibody is added to the sample, and the sample is then con-  
20 tacted with the immobilized *fused*. In this case, the amount of anti-*fused* antibody bound to the immobilized *fused* is inversely proportional to the amount of *fused* present in the sample. Again the amount of immobilized antibody may be detected by detecting either the immobilized fraction of antibody or the fraction of the antibody that remains in solution. Detection may be direct where the antibody is labeled or  
25 indirect by the subsequent addition of a labeled moiety that specifically binds to the antibody as described above.

c) Other assay formats.

In a particularly preferred embodiment, Western blot Immunoblot analysis is used to  
30 detect and quantify the presence of *fused* in the sample. The technique generally

comprises separating sample proteins by gel electrophoresis on the basis of molecular weight, transferring the separated proteins to a suitable solid support, (such as a nitrocellulose filter, a nylon filter, or derivatized nylon filter), and incubating the sample with the antibodies that specifically bind *fused*. The anti-*fused* antibodies specifically bind to *fused* on the solid support. These antibodies may be directly labeled or alternatively may be subsequently detected using labeled antibodies (e.g., labeled sheep anti-mouse antibodies) that specifically bind to the anti-*fused*.

Other assay formats include liposome immunoassays (LIA), which use liposomes designed to bind specific molecules (e.g., antibodies) and release encapsulated reagents or markers. The released chemicals are then detected according to standard techniques (see, Monroe *et al.* (1986) *Amer. Clin. Prod. Rev.* 5:34-41).

#### d) Scoring of the assay.

The assays of this invention are scored (as positive or negative for *fused* polypeptide) according to standard methods well known to those of skill in the art. The particular method of scoring will depend on the assay format and choice of label. For example, a Western Blot assay can be scored by visualizing the colored product produced by the enzymatic label. A clearly visible colored band or spot at the correct molecular weight is scored as a positive result, while the absence of a clearly visible spot or band is scored as a negative. In a preferred embodiment, a positive test will show a signal intensity (e.g., *fused* polypeptide quantity) at least twice that of the background and/or control and more preferably at least 3 times or even at least 5 times greater than the background and/or negative control.

#### e) Reduction of non-specific binding.

One of skill in the art will appreciate that it is often desirable to reduce non-specific binding in immunoassays. Particularly, where the assay involves an antigen or antibody immobilized on a solid substrate it is desirable to minimize the amount of non-specific binding to the substrate. Means of reducing such non-specific binding are

well known to those of skill in the art. Typically, this involves coating the substrate with a proteinaceous composition. In particular, protein compositions such as bovine serum albumin (BSA), nonfat powdered milk, and gelatin are widely used with powdered milk being most preferred.

5

#### f) Labels.

The particular label or detectable group used in the assay is not a critical aspect of the invention, so long as it does not significantly interfere with the specific binding of the antibody used in the assay. The detectable group can be any material having a detectable physical or chemical property. Such detectable labels have been well-developed in the field of immunoassays and, in general, most any label useful in such methods can be applied to the present invention. Thus, a label is any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means. Useful labels in the present invention include magnetic beads (*e.g.*, Dynabeads<sup>TM</sup>), fluorescent dyes (*e.g.*, fluorescein isothiocyanate, texas red, rhodamine, and the like), radiolabels (*e.g.*, <sup>3</sup>H, <sup>125</sup>I, <sup>35</sup>S, <sup>14</sup>C, or <sup>32</sup>P), enzymes (*e.g.*, horse radish peroxidase, alkaline phosphatase and others commonly used in an ELISA), and colorimetric labels such as colloidal gold or colored glass or plastic (*e.g.*, polystyrene, polypropylene, latex, *etc.*) beads.

15  
20

The label may be coupled directly or indirectly to the desired component of the assay according to methods well known in the art. As indicated above, a wide variety of labels may be used, with the choice of label depending on sensitivity required, ease of conjugation with the compound, stability requirements, available instrumentation, and disposal provisions.

25

Non-radioactive labels are often attached by indirect means. Generally, a ligand molecule (*e.g.*, biotin) is covalently bound to the molecule. The ligand then binds to an anti-ligand (*e.g.*, streptavidin) molecule which is either inherently detectable or covalently bound to a signal system, such as a detectable enzyme, a fluorescent

30

compound, or a chemiluminescent compound. A number of ligands and anti-ligands can be used. Where a ligand has a natural anti-ligand, for example, biotin, thyroxine, and cortisol, it can be used in conjunction with the labeled, naturally occurring anti-ligands. Alternatively, any haptenic or antigenic compound can be used in combination with an antibody.

The molecules can also be conjugated directly to signal generating compounds, *e.g.*, by conjugation with an enzyme or fluorophore. Enzymes of interest as labels will primarily be hydrolases, particularly phosphatases, esterases and glycosidases, or oxidoreductases, particularly peroxidases. Fluorescent compounds include fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, *etc.* Chemiluminescent compounds include luciferin, and 2,3-dihydrophthalazinediones, *e.g.*, luminol. For a review of various labeling or signal producing systems which may be used, see, U.S. Patent No. 4,391,904).

Means of detecting labels are well known to those of skill in the art. Thus, for example, where the label is a radioactive label, means for detection include a scintillation counter or photographic film as in autoradiography. Where the label is a fluorescent label, it may be detected by exciting the fluorochrome with the appropriate wavelength of light and detecting the resulting fluorescence. The fluorescence may be detected visually, by means of photographic film, by the use of electronic detectors such as charge coupled devices (CCDs) or photomultipliers and the like. Similarly, enzymatic labels may be detected by providing the appropriate substrates for the enzyme and detecting the resulting reaction product. Finally simple colorimetric labels may be detected simply by observing the color associated with the label.

Thus, in various dipstick assays, conjugated gold often appears pink, while various conjugated beads appear the color of the bead.

Some assay formats do not require the use of labeled components. For instance, agglutination assays can be used to detect the presence of the target antibodies. In this case, antigen-coated particles are agglutinated by samples comprising the target

antibodies. In this format, none of the components need be labeled and the presence of the target antibody is detected by simple visual inspection.

g) Substrates.

5 As mentioned above, depending upon the assay, various components, including the antigen, target antibody, or anti-human antibody, may be bound to a solid surface. Many methods for immobilizing biomolecules to a variety of solid surfaces are known in the art. For instance, the solid surface may be a membrane (*e.g.*, nitrocellulose), a microtiter dish (*e.g.*, PVC, polypropylene, or polystyrene), a test tube  
10 (glass or plastic), a dipstick (*e.g.*, glass, PVC, polypropylene, polystyrene, latex and the like), a microcentrifuge tube, or a glass or plastic bead. The desired component may be covalently bound or noncovalently attached through nonspecific bonding. A wide variety of organic and inorganic polymers, both natural and synthetic, may be employed as the material for the solid surface. Illustrative polymers include poly-  
15 ethylene, polypropylene, poly(4-methylbutene), polystyrene, polymethacrylate, poly(ethylene terephthalate), rayon, nylon, poly(vinyl butyrate), polyvinylidene difluoride (PVDF), silicones, polyformaldehyde, cellulose, cellulose acetate, nitrocellulose, and the like. Other materials which may be employed include paper, glasses, ceramics, metals, metalloids, semiconductive materials, cements or the like. In addition,  
20 are included substances that form gels, such as proteins (*e.g.*, gelatins) lipopolysaccharides, silicates, agarose and polyacrylamides can be used. Polymers which form several aqueous phases, such as dextrans, polyalkylene glycols or surfactants, such as phospholipids, long chain (12-24 carbon atoms) alkyl ammonium salts and the like are also suitable. Where the solid surface is porous, various pore sizes may  
25 be employed depending upon the nature of the system.

In preparing the surface, a plurality of different materials may be employed, particularly as laminates, to obtain various properties. For example, protein coatings, such as gelatin, can be used to avoid non-specific binding, simplify covalent conjugation, enhance signal detection or the like.  
30

If covalent bonding between a compound and the surface is desired, the surface will usually be polyfunctional or be capable of being polyfunctionalized. Functional groups which may be present on the surface and used for linking can include carboxylic acids, aldehydes, amino groups, cyano groups, ethylenic groups, hydroxyl groups, mercapto groups and the like. The manner of linking a wide variety of compounds to various surfaces is well known and is amply illustrated in the literature. See, for example, *Immobilized Enzymes*, Ichiro Chibata, Halsted Press, New York, 1978, and Cuatrecasas (1970) *J. Biol. Chem.* 245 3059).

In addition to covalent binding, various methods for noncovalently binding an assay component can be used. Noncovalent binding is typically nonspecific absorption of a compound to the surface. Typically, the surface is blocked with a second compound to prevent nonspecific binding of labeled assay components. Alternatively, the surface is designed such that it nonspecifically binds one component but does not significantly bind another. For example, a surface bearing a lectin such as Concanavalin A will bind a carbohydrate containing compound but not a labeled protein that lacks glycosylation. Various solid surfaces for use in noncovalent attachment of assay components are reviewed in U.S. Patent Nos. 4,447,576 and 4,254,082.

D) Evaluation of *fused* expression levels and/or abnormal expression.

One of skill will appreciate that abnormal expression levels or abnormal expression products (*e.g.*, mutated transcripts, truncated or non-sense polypeptides) are identified by comparison to normal expression levels and normal expression products.

Normal levels of expression or normal expression products can be determined for any particular population, subpopulation, or group of organisms according to standard methods well known to those of skill in the art. Typically this involves identifying healthy organisms and measuring expression levels of the *fused* gene (as described herein) or sequencing the gene, mRNA, or reverse transcribed cDNA, to obtain typical (normal) sequence variations. Application of standard statistical met-

hods used in molecular genetics permits determination of baseline levels of expression, and normal gene products as well as significant deviations from such baseline levels.

5 E) Detection kits.

The present invention also provides for kits for the diagnosis of organisms (*e.g.*, patients). The kits preferably include one or more reagents for determining the presence or absence of the fused gene, for quantifying expression of the fused gene, or for detecting an abnormal *fused* gene or expression products of an abnormal *fused* gene. Preferred reagents include nucleic acid probes that specifically bind to the normal *fused* gene, cDNA, or subsequence thereof, probes that specifically bind to abnormal *fused* gene (*e.g.*, *fused* containing premature truncations, insertions, or deletions), antibodies that specifically bind to normal *fused* polypeptides or subsequences thereof, or antibodies that specifically bind to abnormal *fused* polypeptides or subsequences thereof. The antibody or hybridization probe may be free or immobilized on a solid support such as a test tube, a microtiter plate, a dipstick and the like. The kit may also contain instructional materials teaching the use of the antibody or hybridization probe in an assay for the detection of a deviation from the normal sequence of a *fused* gene.

20

The kits may include alternatively, or in combination with any of the other components described herein, an anti-*fused* antibody. The antibody can be monoclonal or polyclonal. The antibody can be conjugated to another moiety such as a label and/or it can be immobilized on a solid support (substrate).

25

The kits(s) may also contain a second antibody for detection of polypeptide/antibody complexes according to the invention or for detection of hybridized nucleic acid probes. The kit may contain appropriate reagents for detection of labels, positive and negative controls, washing solutions, dilution buffers and the like.

30

## VI. Modulation of expression of endogenous *fused* genes.

In still another embodiment, this invention provides methods of regulating the expression of endogenous *fused* genes. The expression of a *fused* gene product may be increased. Regulation of *fused* gene may provide a convenient and controllable model system for the study of the HH-PTC pathway, especially in human beings.

Methods of altering the expression of endogenous genes are well known to those of skill in the art. Typically such methods involve altering or replacing all or a portion of the regulatory sequences controlling expression of the particular gene that is to be regulated. In a preferred embodiment, the regulatory sequences (*e.g.*, the native promoter) upstream of the *fused* gene is altered.

This is typically accomplished by the use of homologous recombination to introduce a heterologous nucleic acid into the native regulatory sequences. To downregulate expression the *fused* gene product, simple mutations that either alter the reading frame or disrupt the promoter are suitable. To upregulate expression of the *fused* gene product, the native promoter(s) can be substituted with heterologous promoter(s) that induce higher than normal levels of transcription.

In a particularly preferred embodiment, nucleic acid sequences comprising the structural gene in question or upstream sequences are utilized for targeting heterologous recombination constructs. Upstream and downstream sequences can be readily determined using the information provided herein. Such sequences, for example, can be extended using 5'- or 3'-RACE and homologous recombination constructs created with only routine experimentation.

The use of homologous recombination to alter expression of endogenous genes is described in detail in U.S. Patent 5,272,071, WO 91/09955, WO 93/09222, WO 96/29411, WO 95/31560, and WO 91/12650.

## VII. Therapeutics

### A) Pharmaceutical Compositions

The proteins, polypeptides, antibodies and anti-*fused* antibody-effector (*e.g.*, enzyme toxin, hormone, growth factor, drug, *etc.*) conjugates or fusion proteins of this invention are useful for parenteral, topical, oral, or local administration, such as by aerosol or transdermally, for prophylactic and/or therapeutic treatment. The pharmaceutical compositions can be administered in a variety of unit dosage forms depending upon the method of administration. For example, unit dosage forms suitable for oral administration include powder, tablets, pills, capsules and lozenges. It is recognized that the polypeptides and related compounds described of, when administered orally, must be protected from digestion. This is typically accomplished either by complexing the protein with a composition to render it resistant to acidic and enzymatic hydrolysis or by packaging the protein in an appropriately resistant carrier such as a liposome. Means of protecting proteins from digestion are well known in the art.

The pharmaceutical compositions of this invention may be used for topical administration, *e.g.* to treat basal cell carcinomas, or their precursors, solar keratoses. In another embodiment, the compositions are useful for parenteral administration, such as intravenous administration or administration into a body cavity or lumen of an organ. The compositions for administration will commonly comprise a solution of the polypeptide, antibody or antibody chimera/fusion dissolved in a pharmaceutically acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers can be used, *e.g.*, buffered saline and the like. These solutions are sterile and generally free of undesirable matter. These compositions may be sterilized by conventional, well known sterilization techniques. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, for example, sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like. The concentration of chimeric molecule in these formulations can vary widely, and will be selected primarily based on fluid volu-

mes, viscosities, body weight and the like in accordance with the particular mode of administration selected and the patient's needs.

Thus, a typical pharmaceutical composition for intravenous administration would be about 0.1 to 10 mg per patient per day. Dosages from 0.1 up to about 100 mg per patient per day may be used, particularly when the drug is administered to a secluded site and not into the blood stream, such as into a body cavity or into a lumen of an organ. Substantially higher dosages are possible in topical administration. Actual methods for preparing parenterally administrable compositions will be known or apparent to those skilled in the art and are described in more detail in such publications as *Remington's Pharmaceutical Science*, 15<sup>th</sup>., Mack Publishing Company, Easton, Pennsylvania (1980).

The compositions containing the present polypeptides, antibodies or antibody chimera/fusion, or a cocktail thereof (*i.e.*, with other proteins), can be administered for therapeutic treatments. In therapeutic applications, compositions are administered to a patient suffering from a disease in an amount sufficient to cure or at least partially arrest the disease and its complications. An amount adequate to accomplish this is defined as a "therapeutically effective dose." Amounts effective for this use will depend upon the severity of the disease and the general state of the patient's health.

Single or multiple administrations of the compositions may be administered depending on the dosage and frequency as required and tolerated by the patient. In any event, the composition should provide a sufficient quantity of the proteins of this invention to effectively treat the patient.

#### B) Cellular Transformation and Gene Therapy.

The present invention provides packageable human *fused* nucleic acids (cDNAs) for the transformation of cells *in vitro* and *in vivo*. These packageable nucleic acids can be inserted into any of a number of well known vectors for the transfection and

transformation of target cells and organisms as described below. The nucleic acids are transfected into cells, *ex vivo* or *in vivo*, through the interaction of the vector and the target cell. The *fused* cDNA, under the control of a promoter, then expresses the *fused* protein thereby mitigating the effects of absent *fused* genes or partial inactivation of the *fused* gene or abnormal expression of the *fused* gene.

Such gene therapy procedures have been used to correct acquired and inherited genetic defects, cancer, and viral infection in a number of contexts. The ability to artificial genes in humans facilitates the prevention and/or cure of many important human diseases, including many diseases which are not amenable to treatment by other therapies. As an example, *in vivo* expression of cholesterol-regulating genes, genes which selectively block the replication of HIV, and tumor-suppressing genes in human patients dramatically improves the treatment of heart disease, AIDS, and cancer, respectively. For a review of gene therapy procedures, see Anderson, *Science* (1992) 256:808-813; Nabel and Felgner (1993) *TIBTECH* 11: 211-217; Mitani and Caskey (1993) *TIBTECH* 11: 162-166; Mulligan (1993) *Science* 926-932; Dillon (1993) *TIBTECH* 11: 167-175; Miller (1992) *Nature* 357: 455-460; Van Brunt (1988) *Biotechnology* 6(10): 1149-1154; Vigne (1995) *Restorative Neurology and Neuroscience* 8: 35-36; Kremer and Perricaudet (1995) *British Medical Bulletin* 51(1) 31-44; Haddada *et al.* (1995) in *Current Topics in Microbiology and Immunology* Doerfler and Böhm (eds) Springer-Verlag, Heidelberg Germany; and Yu *et al.*, *Gene Therapy* (1994) 1:13-26.

Delivery of the gene or genetic material into the cell is the first critical step in gene therapy treatment of disease. A large number of delivery methods are well known to those of skill in the art. Such methods include, for example liposome-based gene delivery (Debs and Zhu (1993) WO 93/24640; Mannino and Gould-Fogerite (1988) *BioTechniques* 6(7): 682-691; Rose U.S. Pat No. 5,279,833; Brigham (1991) WO 91/06309; and Felgner *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84: 7413-7414), and replication-defective retroviral vectors harboring a therapeutic polynucleotide

sequence as part of the retroviral genome (*see, e.g., Miller et al. (1990) Mol. Cell. Biol. 10:4239 (1990; Kolberg (1992) J. NIH Res. 4:43, and Cornetta et al. Hum. Gene Ther. 2:215 (1991))*). Widely used retroviral vectors include those based upon murine leukemia virus (MuLV), gibbon ape leukemia virus (GaLV), Simian Immuno deficiency virus (SIV), human immuno deficiency virus (HIV), and combinations thereof. *See, e.g., Buchscher et al. (1992) J. Virol. 66 (5) 2731-2739; Johann et al. (1992) J. Virol. 66 (5):1635-1640 (1992); Sommerfelt et al., (1990) Virol. 176:58-59; Wilson et al. (1989) J. Virol. 63:2374-2378; Miller et al., J Virol. 65:2220-2224 (1991); Wong-Staal et al., PCT/US94/05700, and Rosenberg and Fauci (1993) in* 5  
10 *Fundamental Immunology, Third Edition Paul (ed) Raven Press, Ltd., New York and the references therein, and Yu et al., Gene Therapy (1994) supra*).

AAV-based vectors are also used to transduce cells with target nucleic acids, *e.g., in the in vitro* production of nucleic acids and peptides, and in *in vivo* and *ex vivo* gene 15  
therapy procedures. *See, West et al. (1987) Virology 160:38-47; Carter et al. (1989) U.S. Patent No. 4,797,368; Carter et al. WO 93/24641 (1993); Kotin (1994) Human Gene Therapy 5:793-801; Myzyczka (1994) J. Clin. Invest. 94:1351 and Samulski (supra) for an overview of AAV vectors. Construction of recombinant AAV vectors are described in a number of publications, including Lebkowski, U.S. Pat. No.* 20  
*5,173,414; Tratschin et al. (1985) Mol. Cell. Biol. 5(11):3251-3260; Tratschin, et al. (1984) Mol. Cell. Biol. 4:2072-2081; Hermonat and Muzyczka (1984) Proc. Natl. Acad. Sci. USA 81:6466-6470; McLaughlin et al. (1988) and Samulski et al. (1989) J. Virol. 63:03822-3828. Cell lines that can be transformed by rAAV include those described in Lebkowski et al. (1988) Mol. Cell. Biol. 8:3988-3996.*

25

### VIII.

#### A) Ex vivo transformation of cells.

*Ex vivo* cell transformation for diagnostics, reserach, or for gene therapy (*e.g., via re-infusion of the transformed cells into the host organism*) is well known to those of 30  
skill in the art. In a preferred embodiment, cells are isolated from the subject orga-

nism, transfected with the *fused* gene or cDNA of this invention, and re-infused back into the subject organism (*e.g.*, patient). Various cell types suitable for *ex vivo* transformation are well known to those of skill in the art. Particular preferred cells are progenitor or stem cells (*see, e.g., Freshney et al., m Culture of Animal Cells, a*  
5 *Manual of Basic Technique, third edition* Wiley-Liss, New York (1994)) and the references cited therein for a discussion of how to isolate and culture cells from patients).

As indicated above, in a preferred embodiment, the packageable nucleic acid en-  
10 des a *fused* polypeptide under the control of an activated or constitutive promoter.

In one particularly preferred embodiment, stem cells are used in *ex-vivo* procedures for cell transformation and gene therapy. The advantage to using stem cells is that they can be differentiated into other cell types *in vitro*, or can be introduced into a  
15 mammal (such as the donor of the cells) where they will engraft in the bone marrow. Methods for differentiating CD34<sup>+</sup> cells *in vitro* into clinically important immune cell types using cytokines such as GM-CSF, IFN- $\gamma$  and TNF- $\alpha$  are known (*see, Inaba et al. (1992) J. Exp. Med. 176: 1693-1702, and Szabolcs et al. (1995) 154: 5851-5861*).

20 Stem cells are isolated for transduction and differentiation using known methods. For example, in mice, bone marrow cells are isolated by sacrificing the mouse and cutting the leg bones with a pair of scissors. Stem cells are isolated from bone marrow cells by panning the bone marrow cells with antibodies which bind unwanted  
25 cells, such as CD4<sup>+</sup> and CD8<sup>+</sup> (T cells), CD45<sup>+</sup> (panB cells), GR-1 (granulocytes), and Ia<sup>d</sup> (defferentiated antigen presenting cells). For an example of this protocol *see, Inaba et al. (1992) J. Exp. Med. 176: 1693-1702*.

In humans, bone marrow aspirations from iliac crests are performed *e.g.*, under ge-  
30 neral anesthesia in the operating room. The bone marrow aspirations is approxima-

tely 1,000 ml in quantity and is collected from the posterior iliac bones and crests. If the total number of cells collected is less than about  $2 \times 10^8/\text{kg}$ , a second aspiration using the sternum and anterior iliac crests in addition to posterior crests is performed. During the operation, two units of irradiated packed red cells are administered to replace the volume of marrow taken by the aspiration. Human hematopoietic progenitor and stem cells are characterized by the presence of a CD34 surface membrane antigen. This antigen is used for purification, *e.g.*, on affinity columns which bind CD34. After the bone marrow is harvested, the mononuclear cells are separated from the other components by means of ficoll gradient centrifugation. This is performed by a semi-automated method using a cell separator (*e.g.*, a Baxter Fenwal CS3000+ or Terumo machine). The light density cells, composed mostly of mononuclear cells are collected and the cells are incubated in plastic flasks at 37°C for 1.5 hours. The adherent cells (monocytes, macrophages and B-Cells) are discarded. The non-adherent cells are then collected and incubated with a monoclonal anti-CD34 antibody (*e.g.*, the murine antibody 9C5) at 4°C for 30 minutes with gentle rotation. The final concentration for the anti-CD34 antibody is 10 µg/ml. After two washes, paramagnetic microspheres (DynaBeads, supplied by Baxter Immunotherapy Group, Santa Ana, California) coated with sheep antimouse IgG (Fc) antibody are added to the cell suspension at a ratio of 2 cells/bead. After a further incubation period of 30 minutes at 4°C, the rosetted cells with magnetic beads are collected with a magnet. Chymopapain (supplied by Baxter Immunotherapy Group, Santa Ana, California) at a final concentration 200 U/ml is added to release the beads from the CD34+ cells. Alternatively, and preferably, an affinity column isolation procedure can be used which binds to CD34, or to antibodies bound to CD34 (*see*, the examples below). *See*, Ho *et al.* (1995) *Stem Cells* 13 (Suppl. 3): 100-105. *See also*, Brenner (1993) *Journal of hematotherapy* 2: 7-17.

In another embodiment, hematopoietic stem cells are isolated from fetal cord blood. Yu *et al.* (1995) *Proc. Natl. Acad. Sci. USA* 92: 699-703 describe a preferred met-

hod of transducing CD34<sup>+</sup> cells from human fetal cord blood using retroviral vectors.

B) *In vivo* transformation

- 5 Vectors (*e.g.*, retroviruses, adenoviruses, liposomes, *etc.*) containing therapeutic nucleic acids can be administered directly to the organism for transduction of cells *in vivo*. Administration is by any of the routes normally used for introducing a molecule into ultimate contact with blood or tissue cells. The packaged nucleic acids are administered in any suitable manner, preferably with pharmaceutically acceptable carriers. Suitable methods of administering such packaged nucleic acids are available and well known to those of skill in the art, and, although more than one route can be used to administer a particular composition, a particular route can often provide a more immediate and more effective reaction than another route.
- 15 Pharmaceutically acceptable carriers are determined in part by the particular composition being administered, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions of the present invention.
- 20 Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of the packaged nucleic acid suspended in diluents, such as water, saline or PEG 400; (b) capsules, sachets or tablets, each containing a predetermined amount of the active ingredient, as liquids, solids, granules or gelatin; (c) suspensions in an appropriate liquid; and (d) suitable emulsions. Tablet forms can include one or more of lactose, sucrose, mannitol, sorbitol, calcium phosphates, corn starch, potato starch, tragacanth, microcrystalline cellulose, acacia, gelatin, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, stearic acid, and other excipients, colorants, fillers, binders, diluents, buffering agents, moistening agents, preservatives, flavoring agents, dyes, disintegrating agents, and pharmaceutically compatible carriers. Lozenge forms can comprise the active ingredient in a
- 30

flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addition to the active ingredient, carriers known in the art.

5

The packaged nucleic acids, alone or in combination with other suitable components, can be made into aerosol formulations (*i.e.*, they can be "nebulized") to be administered via inhalation. Aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like.

10

Suitable formulations for rectal administration include, for example, suppositories, which consist of the packaged nucleic acid with a suppository base. Suitable suppository bases include natural or synthetic triglycerides or paraffin hydrocarbons. In addition, it is also possible to use gelatin rectal capsules which consist of a combination of the packaged nucleic acid with a base, including, for example, liquid triglycerides, polyethylene glycols, and paraffin hydrocarbons.

15

Formulations suitable for parenteral administration, such as, for example, by intra-articular (in the joints), intravenous, intramuscular, intradermal, intraperitoneal, and subcutaneous routes, include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. In the practice of this invention, compositions can be administered, for example, by intravenous infusion, orally, topically, intraperitoneally, intravesically or intrathecally. Parenteral administration and intravenous administration are the preferred methods of administration. The formulations of packaged nucleic acid can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials.

20

25

30

Injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described. Cells transduced by the packaged nucleic acid as described above in the context of *ex vivo* therapy can also be administered intravenously or parenterally as described above.

5

The dose administered to a patient, in the context of the present invention should be sufficient to effect a beneficial therapeutic response in the patient over time. The dose will be determined by the efficacy of the particular vector employed and the condition of the patient, as well as the body weight or surface area of the patient to be treated. The size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects that accompany the administration of a particular vector, or transduced cell type in a particular patient.

For administration, inhibitors and transduced cells of the present invention can be administered at a rate determined by the LD-50 of the inhibitor, vector, or transduced cell type, and the side-effects of the inhibitor, vector or cell type at various concentrations, as applied to the mass and overall health of the patient. Administration can be accomplished via single or divided doses.

In a preferred embodiment, prior to infusion, blood samples are obtained and saved for analysis. Between  $1 \times 10^8$  and  $1 \times 10^{12}$  transduced cells are infused intravenously over 60-200 minutes. Vital signs and oxygen saturation by pulse oximetry are closely monitored. Blood samples are obtained 5 minutes and 1 hour following infusion and saved for subsequent analysis. Leukopheresis, transduction and reinfusion can be repeated every 2 to 3 months. After the first treatment, infusions can be performed on an outpatient basis at the discretion of the clinician. If the reinfusions is given as an outpatient, the participant is monitored for at least 4, and preferably 8 hours following the therapy.

Transduced cells are prepared for reinfusion according to established methods. See, Abrahamsen *et al.* (1991) *J. Clin. Apheresis*, 6: 48-53; Carter *et al.* (1988) *J. Clin.*

*Apheresis*, 4:113-117; Aebersold *et al.* (1988) *J. Immunol. Meth.*, 112: 1-7; Muul *et al.* (1987) *J. Immunol. Methods* 101:171-181 and Carter *et al.* (1987) *Transfusion* 27: 362-365. After a period of about 2-4 weeks in culture, the cells should number between  $1 \times 10^8$  and  $1 \times 10^{12}$ . In this regard, the growth characteristics of cells vary from patient to patient and from cell type to cell type. About 72 hours prior to reinfusion of the transduced cells, an aliquot is taken for analysis of phenotype, and percentage of cells expressing the therapeutic agent.

### EXAMPLES

- 10 The following examples are offered to illustrate, but not to limit the present invention.

#### Cloning of a human Fused homolog.

- By searching the EST database a partial cDNA clone (GenBank Acc: F07835) was identified having significant sequence identity with the *Drosophila* Fused. Based on the sequence of this clone. PCR primers were designed in order to use the RACE technology to isolate the missing sequence of the human homolog (Zaphiropoulos and Toftgard, DNA Cell Biology, 15, 1049-1056, 1996). The PCR primers used to extend the sequence in the 5' direction from epidermal cDNA were 5' AGA TGC GAC GGC TGG GGT C and 5' GCG TCG ACT GCA GTA GGT CCC GGC AGT CTC (nested primer). The PCR primers used to extend the sequence in the 3' direction from epidermal cDNA were 5' TCT TCG GGC AGC CCC CCT T and 5' GCG TCG ACG TTC TCG GAG CTG GAA GAG AAG AT (nested primer).
- 25 The products of the RACE amplification were cloned into the pGEM 5 vector (Promega) and sequenced with dye-dideoxy nucleotides using the facilities of Cybergene AB.

Two additional splice variants of the human fused homolog were also identified.

- 30 Variant I had 4 extra nucleotides (GTAG) between positions 124 and 125, and

splice variant II lacked the 7 nucleotides (GTGTGCA) at positions 118 to 124. In these variant 5' sequences there are no methionine codons in frame with the remaining fused sequence, but instead termination codons, suggesting that a downstream methionine or non-methionine codons are likely to be used for translation initiation.

#### Cloning of a human fused homolog.

By searching the EST database a partial cDNA clone (GenBank Acc: F07835) was identified having significant sequence identity with the drosophila fused. Based on the sequence of this clone, PCR primers were designed in order to use the RACE technology to isolate the missing sequence of the human homolog (Zaphiropoulos and Toftgård, DNA Cell Biology, 15, 1049-1056, 19969). The PCR primers used to extend the sequence in the 5' direction from epidermal cDNA were 5' AGA TGC GAC GGC TGG GGT C and 5' GCG TCG ACT GCA GTA GGT CCC GGC AGT CTC (nested primer). The PCR primers used to extend the sequence in the 3' direction from epidermal cDNA were 5' TCT TCG GGC AGC CCC CCT T and 5' GCG TCG ACG TTC TCG GAG CTG GAA GAG AAG AT (nested primer).

The product of the RACE amplification were cloned into the pGEM 5 vector (Promega) and sequenced with dye-dideoxy nucleotides using the facilities of Cybergene AB.

Two additional splice variants of the human fused homolog were also identified. Variant I had 4 extra nucleotides (GTAG) between positions 124 and 125, and splice variant II lacked the 7 nucleotides (GTGTGCA) at positions 118 to 124. In these variant 5' sequences there are no methionine codons in frame with the remaining fused sequence, but instead termination codons, suggesting that a downstream methionine or non-methionine codons are likely to be used for translation initiation.

The human fused homolog has the following properties:

- a. 33,5% amino acid identity with Drosophila fused (within the kinase domain the identity increases to 37,0%).
- b. 54,0% amino acid similarity with Drosophila fused (within the kinase domain the similarity increases to 59,9%).
- 5 c. Detected mRNA expresion in epidermis, pancreas, kidney, skeletal muscle, liver, placeta brain, with highest levels in lung.
4. Observed evolutionary conservation in other species including monkey, rat, mouse, dog and cow.

CLAIMS

1. An isolated protein molecule capable of involvement in eliciting an intracellular signal in the human HH-PTC pathway and exhibiting a substantial similarity with the sequence disclosed in SEQ ID NO 2.
- 5 2. A protein according to claim 1, which exhibits a sequence similarity of about 80% with the sequence disclosed in SEQ ID NO 2.
3. A protein according to claim 1 or 2, which is comprised of the amino acid  
10 sequence disclosed in SEQ ID NO 2, or an analogue or functional equivalent thereof.
4. An isolated polypeptide capable of involvement in eliciting an intracellular signal in the human HH-PTC pathway and comprised of a subsequence of about 8-15 con-  
15 tiguous amino acids of the sequence disclosed in SEQ ID NO 2.
5. A polypeptide according to claim 4 comprised of 10 contiguous amino acids of the sequence disclosed in SEQ ID NO 2.
- 20 6. A polypeptide according to claim 4 or 5 for use as a medicament.
7. A substance capable of activating or inhibiting a protein according to any one of claims 1-3 or a polypeptide according to claim 4 or 5, which substance is characterized in the Kinase-regulating property thereof.
- 25 8. A substance according to claim 7 for use as a medicament.
9. A DNA sequence encoding a protein according to any one of claims 1-3; or a variant thereof.

10. A DNA sequence encoding a polypeptide according to claim 4 or 5, or a variant thereof.

11. An isolated human DNA sequence capable of involvement in eliciting an intracellular signal in the HH-PTCH pathway comprising essentially all of the sequence as disclosed in SEQ ID NO 1.

12. A vector comprising such a DNA sequence as defined in any one of claims 9-11.

13. An expression cassette comprising such a DNA sequence as defined in any one of claims 9-11.

14. A cell comprising such an expression cassette as defined in claim 13 or a vector according to claim 12.

15. An antibody which specifically binds to such a polypeptide as defined in claim 4 or 5.

16. An antibody according to claim 15, which is a monoclonal antibody.

17. A recombinant cell expressing such an antibody as defined in claim 15 or 16.

18. An antibody according to claim 15 or 16 for use as a medicament.

19. A pharmaceutical composition which comprises a polypeptide according to claim 4 or 5 and a pharmaceutically acceptable carrier.

20. A kit for detection of a human *fused* gene; which kit comprises a nucleic acid sequence capable of hybridising specifically with the sequence disclosed in SEQ ID

NO 1.

21. A kit for detection of a protein encoded by a human *fused* gene, comprising a container containing such an antibody as defined in claim 15 or 16.

SEQUENCE LISTING

## (1) GENERAL INFORMATION:

## (i) APPLICANT:

- (A) NAME: Karolinska Innovations AB  
 (B) STREET: Karolinska Institutet  
 (C) CITY: Stockholm  
 (E) COUNTRY: SWEDEN  
 (F) POSTAL CODE (ZIP): 171 77

## (ii) TITLE OF INVENTION: FUSED GENE

## (iii) NUMBER OF SEQUENCES: 2

## (iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk  
 (B) COMPUTER: IBM PC compatible  
 (C) OPERATING SYSTEM: PC-DOS/MS-DOS  
 (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

## (2) INFORMATION FOR SEQ ID NO: 1:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2644 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (iii) HYPOTHETICAL: NO

## (iv) ANTI-SENSE: YES

## (ix) FEATURE:

- (A) NAME/KEY: CDS  
 (B) LOCATION: 90..1533

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

```

CTGGGGTCCC CCGCGCCTGG ACGGCTTCAT CCTACCGAG CGCCTGGGCA GCGGCACGTA    60
CGCCACGGTG TACAAGGCCT ACGCCAAGA ATG CAA AGA AAT GGA TCA GCT AGC      113
               Met  Gln  Arg  Asn  Gly  Ser  Ala  Ser
                   1          5

CGA GGG TTG GAG AAG ACC AGG CTG AGG CTG TGT CGG GAA GCC AGG ATT      161
Arg  Gly  Leu  Glu  Lys  Thr  Arg  Leu  Arg  Leu  Cys  Arg  Glu  Ala  Arg  Ile
    10          15          20

CCA GAA TCA GCA TTC CTC ACT GGC CTC ACA AGG GAA AGC TGG GAA GCC      209
Pro  Glu  Ser  Ala  Phe  Leu  Thr  Gly  Leu  Thr  Arg  Glu  Ser  Trp  Glu  Ala
    25          30          35          40

```

WO 99/32609

PCT/SE98/02384

CGG TGC TGG TGT GCA AAG GAC ACT CGT GAA GTG GTA GCC ATA AAG TGT	257
Arg Cys Trp Cys Ala Lys Asp Thr Arg Glu Val Val Ala Ile Lys Cys	
45 50 55	
GTA GCC AAG AAA AGT CTG AAC AAG GCA TCG GTG GAG AAC CTC CTC ACG	305
Val Ala Lys Lys Ser Leu Asn Lys Ala Ser Val Glu Asn Leu Leu Thr	
60 65 70	
GAG ATT GAG ATC CTC AAG GGC ATT CGA CAT CCC CAC ATT GTG CAG CTG	353
Glu Ile Glu Ile Leu Lys Gly Ile Arg His Pro His Ile Val Gln Leu	
75 80 85	
AAA GAC TTT CAG TGG GAC AGT GAC AAT ATC TAC CTC ATC ATG GAG TTT	401
Lys Asp Phe Gln Trp Asp Ser Asp Asn Ile Tyr Leu Ile Met Glu Phe	
90 95 100	
TGC GCA GGG GGC GAC CTG TCT CGC TTC ATC CAT ACC CGC AGG ATT CTG	449
Cys Ala Gly Gly Asp Leu Ser Arg Phe Ile His Thr Arg Arg Ile Leu	
105 110 115 120	
CCT GAG AAG GTG GCG CGT GTC TTC ATG CAG CAA TTA GCT AGC GCC CTG	497
Pro Glu Lys Val Ala Arg Val Phe Met Gln Gln Leu Ala Ser Ala Leu	
125 130 135	
CAA TTC CTG CAT GAA CGG AAT ATC TCT CAC CTG GAT CTG AAG CCA CAG	545
Gln Phe Leu His Glu Arg Asn Ile Ser His Leu Asp Leu Lys Pro Gln	
140 145 150	
AAC ATT CTA CTG AGC TCC TTG GAG AAG CCC CAC CTA AAA CTG GCA GAC	593
Asn Ile Leu Leu Ser Ser Leu Glu Lys Pro His Leu Lys Leu Ala Asp	
155 160 165	
TTT GGT TTC GCA CAA CAC ATG TCC CCG TGG GAT GAG AAG CAC GTG CTC	641
Phe Gly Phe Ala Gln His Met Ser Pro Trp Asp Glu Lys His Val Leu	
170 175 180	
CGT GGC TCC CCC CTC TAC ATG GCC CCC GAG ATG GTG TGC CAG CGG CAG	689
Arg Gly Ser Pro Leu Tyr Met Ala Pro Glu Met Val Cys Gln Arg Gln	
185 190 195 200	
TAT GAC GCC CGC GTG GAC CTC TGG TCC ATG GGG GTC ATC CTG TAT GAA	737
Tyr Asp Ala Arg Val Asp Leu Trp Ser Met Gly Val Ile Leu Tyr Glu	
205 210 215	
GCC CTC TTC GGG CAG CCC CCC TTT GCC TCC AGG TCG TTC TCG GAG CTG	785
Ala Leu Phe Gly Gln Pro Pro Phe Ala Ser Arg Ser Phe Ser Glu Leu	
220 225 230	
GAA GAG AAG ATC CGT AGC AAC CGG GTC ATC GAG CTC CCC TTG CGG CCC	833
Glu Glu Lys Ile Arg Ser Asn Arg Val Ile Glu Leu Pro Leu Arg Pro	
235 240 245	
CTG CTC TCC CGA GAC TGC CGG GAC CTA CAG CAG CGG CTC CTG GAG CGG	881
Leu Leu Ser Arg Asp Cys Arg Asp Leu Gln Gln Arg Leu Leu Glu Arg	
250 255 260	
GAC CCC AGC CGT CGC ATC TCC TTC CAG GAC TTC TTT GCG CAC CCC TGG	929
Asp Pro Ser Arg Arg Ile Ser Phe Gln Asp Phe Phe Ala His Pro Trp	
265 270 275 280	

GTG GAC CTG GAG CAC ATG CCC AGT GGG GAG AGT CTG GGG CGA GCA ACC 977  
 Val Asp Leu Glu His Met Pro Ser Gly Glu Ser Leu Gly Arg Ala Thr  
 285 290 295

GCC CTG GTG GTG CAG GCT GTG AAG AAA GAC CAG GAG GGG GAT TCA GCA 1025  
 Ala Leu Val Val Gln Ala Val Lys Lys Asp Gln Glu Gly Asp Ser Ala  
 300 305 310

GCC GCC TTA TCA CTC TAC TGC AAG GCT CTG GAC TTC TTT GTA CCT GCC 1073  
 Ala Ala Leu Ser Leu Tyr Cys Lys Ala Leu Asp Phe Phe Val Pro Ala  
 315 320 325

CTG CAC TAT GAA GTG GAT GCC CAG CGG AAG GAG GCA ATT AAG GCA AAG 1121  
 Leu His Tyr Glu Val Asp Ala Gln Arg Lys Glu Ala Ile Lys Ala Lys  
 330 335 340

GTG GGG CAG TAC GTG TCC CGG GCT GAG GAG CTC AAG GCC ATC GTC TCC 1169  
 Val Gly Gln Tyr Val Ser Arg Ala Glu Glu Leu Lys Ala Ile Val Ser  
 345 350 355 360

TCT TCC AAT CAG GCC CTG CTG AGG CAG GGG ACC TCT GCC CGA GAC CTG 1217  
 Ser Ser Asn Gln Ala Leu Leu Arg Gln Gly Thr Ser Ala Arg Asp Leu  
 365 370 375

CTC AGA GAG ATG GCC CGG GAC AAG CCA CGC CTC CTA GCT GCC CTG GAA 1265  
 Leu Arg Glu Met Ala Arg Asp Lys Pro Arg Leu Leu Ala Ala Leu Glu  
 380 385 390

GTG GCT TCA GCT GCC ATG GCC AAG GAG GAG GCC GCC GGC GGG GAG CAG 1313  
 Val Ala Ser Ala Ala Met Ala Lys Glu Glu Ala Ala Gly Gly Glu Gln  
 395 400 405

GAT GCC CTG GAC CTG TAC CAG CAC AGC CTG GGG GAG CTA CTG CTG TTG 1361  
 Asp Ala Leu Asp Leu Tyr Gln His Ser Leu Gly Glu Leu Leu Leu Leu  
 410 415 420

CTG GCA GCG GAG CCC CCG GGC CGG AGG CGG GAG CTG CTT CAC ACT GAG 1409  
 Leu Ala Ala Glu Pro Pro Gly Arg Arg Arg Glu Leu Leu His Thr Glu  
 425 430 435 440

GTT CAG AAC CTC ATG GCC CGA GCT GAA TAC TTG AAG GAG CAG ATG AGG 1457  
 Val Gln Asn Leu Met Ala Arg Ala Glu Tyr Leu Lys Glu Gln Met Arg  
 445 450 455

GAA TCT CGC TGG GAA GCT GAC ACC CTG GAC AAA GAG GGA CTG TCG GAA 1505  
 Glu Ser Arg Trp Glu Ala Asp Thr Leu Asp Lys Glu Gly Leu Ser Glu  
 460 465 470

TCT GTT CGT AGC TCT TGC ACC CTT CAG T GACCCTAGAA GAATGATTGG 1553  
 Ser Val Arg Ser Ser Cys Thr Leu Gln  
 475 480

ACAGATGTGA GCCATCTGGA GCAGAGGGGC ACTAACCCAG GCTGACGCCA AGAATGAAGT 1613

GGCCCACTGC AGCCCTGGCG AGCAGGCTTC TTGGATGGAC AGTGCTGAGA CCCCCATATC 1673

CCAGAGTCCC CAGCCTCCCT CAGGTTACTC TGCACCCAC AGATGGTTTG ATGGCTGTGC 1733

TGTATACTGG AGGGGAGGGC AGGACTCTGG GAGAACAGCA CTTCTTTCAT GAGACCTTTG 1793  
 TTA CTGGTG GTTACTGGGT CCTGTGCCTG TCCGTTTTGG GGCATGCAGC CCTCTATCAT 1853  
 TTTTGGCTCC GAGAAGAGGG CAAGGGGCCC CCGCAGGGTA CTTCTGTGCT TGCCCTCGCC 1913  
 CTGCCAGCAG GCAGCTGTGC CCCTGGCCTG CCCTTCCCGG GACCCCTTAT TCCA ACTCAG 1973  
 CTCCTCTTTG CACTGGAATG GGGCACTCCA ACACCCCTCA GGGACCACCC TCCCCACAGT 2033  
 ATGCACTCAG CCCCACAGAA CCCACCAGTC TTTCTGGGAA CTCACACCTG CCCGCCATCT 2093  
 TGGTACTTTA GGTAAATCCC TCAAGCATGA AAGCTGGATC TTTTGGGGTT TAAGAAGCCC 2153  
 AAGCCTTGTT CCTGCCCTGG CCTAGGGAGC ACTCAGGAGG GTTCCTTGGT CCTCATCTCT 2213  
 CCCACCTCCG TTCCCTCTGG GCCCCACACT AGCCACAGCG CGGGCCTTGT GCTGGAGTTT 2273  
 GAGCCTGGGA CAGGGAGAGG GAGGCTTGGA GACAGTCTGA CCCAGTGCCC TCTAGGCCAC 2333  
 CCACTTCTAG GCCTGCCCTG CCGCCGTGGA GCCCTGGGCA AGCTCTTTCC CCTTTCTGGG 2393  
 CCTGGGTCTC CCCATCTCTT CAATGGGGCT GATACCTTCA CAGCCCACAG CATGGCACTT 2453  
 ATGAGGACAA AGTGAATTTA ACCTGGAAAA GAATGTATTT GAGAGTTTCT TTAAATAAT 2513  
 CAGCGGGTGT TGGTGATTTG TAGCCCTTCT GCCCTTAAAT GCTTCCTTGG GCAAGAGCTG 2573  
 TCTGTCCTCC CTGCAGGAGG CTGAGTGTGA AGAGTATCAT TCATTGTTTC TTTATTAAAT 2633  
 TATTTTCTCT A 2644

## (2) INFORMATION FOR SEQ ID NO: 2:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 481 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Met Gln Arg Asn Gly Ser Ala Ser Arg Gly Leu Glu Lys Thr Arg Leu  
 1 5 10 15

Arg Leu Cys Arg Glu Ala Arg Ile Pro Glu Ser Ala Phe Leu Thr Gly  
 20 25 30

Leu Thr Arg Glu Ser Trp Glu Ala Arg Cys Trp Cys Ala Lys Asp Thr  
 35 40 45

Arg Glu Val Val Ala Ile Lys Cys Val Ala Lys Lys Ser Leu Asn Lys  
 50 55 60

Ala Ser Val Glu Asn Leu Leu Thr Glu Ile Glu Ile Leu Lys Gly Ile  
 65 70 75 80

Arg His Pro His Ile Val Gln Leu Lys Asp Phe Gln Trp Asp Ser Asp  
85 90 95

Asn Ile Tyr Leu Ile Met Glu Phe Cys Ala Gly Gly Asp Leu Ser Arg  
100 105 110

Phe Ile His Thr Arg Arg Ile Leu Pro Glu Lys Val Ala Arg Val Phe  
115 120 125

Met Gln Gln Leu Ala Ser Ala Leu Gln Phe Leu His Glu Arg Asn Ile  
130 135 140

Ser His Leu Asp Leu Lys Pro Gln Asn Ile Leu Leu Ser Ser Leu Glu  
145 150 155 160

Lys Pro His Leu Lys Leu Ala Asp Phe Gly Phe Ala Gln His Met Ser  
165 170 175

Pro Trp Asp Glu Lys His Val Leu Arg Gly Ser Pro Leu Tyr Met Ala  
180 185 190

Pro Glu Met Val Cys Gln Arg Gln Tyr Asp Ala Arg Val Asp Leu Trp  
195 200 205

Ser Met Gly Val Ile Leu Tyr Glu Ala Leu Phe Gly Gln Pro Pro Phe  
210 215 220

Ala Ser Arg Ser Phe Ser Glu Leu Glu Glu Lys Ile Arg Ser Asn Arg  
225 230 235 240

Val Ile Glu Leu Pro Leu Arg Pro Leu Leu Ser Arg Asp Cys Arg Asp  
245 250 255

Leu Gln Gln Arg Leu Leu Glu Arg Asp Pro Ser Arg Arg Ile Ser Phe  
260 265 270

Gln Asp Phe Phe Ala His Pro Trp Val Asp Leu Glu His Met Pro Ser  
275 280 285

Gly Glu Ser Leu Gly Arg Ala Thr Ala Leu Val Val Gln Ala Val Lys  
290 295 300

Lys Asp Gln Glu Gly Asp Ser Ala Ala Ala Leu Ser Leu Tyr Cys Lys  
305 310 315 320

Ala Leu Asp Phe Phe Val Pro Ala Leu His Tyr Glu Val Asp Ala Gln  
325 330 335

Arg Lys Glu Ala Ile Lys Ala Lys Val Gly Gln Tyr Val Ser Arg Ala  
340 345 350

Glu Glu Leu Lys Ala Ile Val Ser Ser Ser Asn Gln Ala Leu Leu Arg  
355 360 365

Gln Gly Thr Ser Ala Arg Asp Leu Leu Arg Glu Met Ala Arg Asp Lys  
370 375 380

Pro Arg Leu Leu Ala Ala Leu Glu Val Ala Ser Ala Ala Met Ala Lys  
385 390 395 400

WO 99/32609

PCT/SE98/02384

Glu Glu Ala Ala Gly Gly Glu Gln Asp Ala Leu Asp Leu Tyr Gln His  
405 410 415

Ser Leu Gly Glu Leu Leu Leu Leu Leu Ala Ala Glu Pro Pro Gly Arg  
420 425 430

Arg Arg Glu Leu Leu His Thr Glu Val Gln Asn Leu Met Ala Arg Ala  
435 440 445

Glu Tyr Leu Lys Glu Gln Met Arg Glu Ser Arg Trp Glu Ala Asp Thr  
450 455 460

Leu Asp Lys Glu Gly Leu Ser Glu Ser Val Arg Ser Ser Cys Thr Leu  
465 470 475 480

Gln

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 98/02384

## A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C12N 9/12, C07K 16/40, A61K 38/45  
According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C12N, C07K, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Letters To Nature, Volume 347, Sept 1990, Thomas Pr��at et al, "A putative serine/threonine protein kinase encoded by the segment-polarity fused ene of Drosophila", page 87 - page 89, figure 3  --	1-5,9-17, 19-21
A	Current biology, Volume 8, No 10, May 1998, V��ronique Monnier et al, "Suppressor of fused links Fused an Cubitus interruptus on the Hedgehog signalling pathway", page 583 - page 586, page 583, last paragraph - page 586, first paragraph  -- -----	1-5,9-17, 19-21

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

2 February 1999

Name and mailing address of the ISA/  
Swedish Patent Office  
Box 5055, S-102 42 STOCKHOLM  
Facsimile No. +46 8 666 02 86

Date of mailing of the international search report

27 -03- 1999

Authorized officer

Patrick Andersson  
Telephone No. +46 8 782 25 00

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 98/02384

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 6 and 18  
because they relate to subject matter not required to be searched by this Authority, namely:  
See PCT Rule 39.1(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.
2. ☒ Claims Nos.: 7-8  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
PCT Article 6, since it is not possible from the description to predict the scope of the claim without due burden.
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

THIS PAGE BLANK (USPTO)